New! View global litigation for patent families

US6011155A - N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV - Google Patents

N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV Download PDF

Info

Publication number
US6011155A
US6011155A US08962168 US96216897A US6011155A US 6011155 A US6011155 A US 6011155A US 08962168 US08962168 US 08962168 US 96216897 A US96216897 A US 96216897A US 6011155 A US6011155 A US 6011155A
Authority
US
Grant status
Grant
Patent type
Prior art keywords
cyano
ex
pyrrolidine
acetyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08962168
Inventor
Edwin Bernard Villhauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

N-(N'-substituted glycyl)-2-cyanopyrrolidines of formula I ##STR1## Compounds of formula I inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

Description

This application claims the benefit of Provisional Application number 60/030,570 filed on Nov. 7, 1996.

FIELD OF THE INVENTION

The present invention relates to the area of dipeptidyl peptidase-TV (DPP-IV) inhibition. DPP-IV is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. Although the biological role of DPP-IV in mammalian systems has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into lymphoid cells.

More recently, it was discovered that DPP-IV is responsible for inactivating glucagon-like peptide-1 (GLP-1). More particularly, DPP-IV cleaves the amino-terminal His-Ala dipeptide of GLP-1, generating a GLP-1 receptor antagonist, and thereby shortens the physiological response to GLP-1. Since the half-life for DPP-IV cleavage is much shorter than the half-life for removal of GLP-1 from circulation, a significant increase in GLP-1 bioactivity (5- to 10-fold) is anticipated from DPP-IV inhibition. Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, DPP-IV inhibition appears to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (NIDDM).

SUMMARY OF THE INVENTION

The present invention provides new DPP-IV inhibitors which are effective in treating conditions mediated by DPP-IV. More particularly, the present invention relates to certain N-(substituted glycyl)-2-cyanopyrrolidines which inhibit DPP-IV. In addition, the present invention provides pharmaceutical compositions useful in inhibiting DPP-IV comprising a therapeutically effective amount of a N-(substituted glycyl)-2-cyanopyrrolidine disclosed herein. Moreover, the present invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a N-(substituted glycyl)-2-cyanopyrrolidine.

DETAILED DESCRIPTION OF THE INVENTION

The instant invention relates to novel N-(substituted glycyl)-2-cyanopyrrolidines of formula I: ##STR2## wherein R is: a) R1 R1a N(CH2)m - wherein

R1 is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;

R1a is hydrogen or (C1-8)alkyl; and

m is2or3;

b) (C3-12)cycloalkyl optionally monosubstituted in the 1-position with (C1-3)hydroxyalkyl;

c) R2 (CH2)n - wherein either

R2 is phenyl optionally mono- or independently di- or independently trisubstituted with (C1-4)alkyl, (C1-4)alkoxy, halogen or phenylthio optionally monosubstituted in the phenyl ring with hydroxymethyl; or is (C1-8)alkyl; a [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C1-8)alkyl; a pyridinyl or naphthyl moiety optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen; cyclohexene; or adamantyl; and

n is 1 to 3; or

R2 is phenoxy optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen; and

n is 2 or 3;

d) (R3)2 CH(CH2)2 - wherein each R3 independently is phenyl optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;

e) R4 (CH2)p - wherein R4 is 2-oxopyrrolidinyl or (C2-4)alkoxy and p is2to4;

f) isopropyl optionally monosubstituted in 1-position with (C1-3)hydroxyalkyl;

g) R5 wherein R5 is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C1-8)alkyl; adamantyl; or (C1-8)alkyl optionally mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl optionally mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;

in free form or in acid addition salt form.

The compounds of formula I can exist in free form or in acid addition salt form. Salt forms may be recovered from the free form in known manner and vice-versa. Acid addition salts may e.g. be those of pharmaceutically acceptable organic or inorganic acids. Although the preferred acid addition salts are the hydrochlorides, salts of methanesulfonic, sulfuric, phosphoric, citric, lactic and acetic acid may also be utilized.

The compounds of the invention may exist in the form of optically active isomers or diastereoisomers and can be separated and recovered by conventional techniques, such as chromatography.

"Alkyl" and "alkoxy" are either straight or branched chain, of which examples of the latter are isopropyl and tert-butyl.

R preferably is a), b) or e) as defined above. R1 preferably is a pyridinyl or pyrimidinyl moiety optionally substituted as defined above. R1a preferably is hydrogen. R2 preferably is phenyl optionally substituted as defined above. R3 preferably is unsubstituted phenyl. R4 preferably is alkoxy as defined above. R5 preferably is optionally substituted alkyl as defined above. m preferably is 2. n preferably is 1 or 2, especially 2. p preferably is 2 or 3, especially 3.

Pyridinyl preferably is pyridin-2-yl; it preferably is unsubstituted or monosubstituted, preferably in 5-position. Pyrimidinyl preferably is pyrimidin-2-yl. It preferably is unsubstituted or monosubstituted, preferably in 4-position. Preferred as substitutents for pyridinyl and pyrimidinyl are halogen, cyano and nitro, especially chlorine.

When it is substituted, phenyl preferably is monosubstituted; it preferably is substituted with halogen, preferably chlorine, or methoxy. It preferably is substituted in 2-, 4- and/or 5-position, especially in 4-position.

(C3-12)cycloalkyl preferably is cyclopentyl or cyclohexyl. When it is substituted, it preferably is substituted with hydroxymethyl. (C1-4)alkoxy preferably is of I or 2 carbon atoms, it especially is methoxy. (C2-4)alkoxy preferably is of 3 carbon atoms, it especially is isopropoxy. Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, especially chlorine. (C1-8)alkyl preferably is of 1 to 6, preferably I to 4 or 3 to 5, especially of 2 or 3 carbon atoms, or methyl. (C1-4) alkyl preferably is methyl or ethyl, especially methyl. (C1-3)hydroxyalkyl preferably is hydroxymethyl.

A [3.1.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[3.1.1]hept-2-yl optionally disubstituted in 6-position with methyl, or bicyclo[3.1.1]hept-3-yl optionally trisubstituted with one methyl in 2-position and two methyl groups in 6-position. A [2.2.1]bicyclic carbocyclic moiety optionally substituted as defined above preferably is bicyclo[2.2.1]hept-2-yl.

Naphthyl preferably is 1-naphthyl. Cyclohexene preferably is cyclohex-1-en-1-yl. Adamantyl preferably is 1- or 2-adamantyl.

A pyrrolidinyl or piperidinyl moiety optionally substituted as defined above preferably is pyrrolidin-3-yl or piperidin-4yl. When it is substituted it preferably is N-substituted.

A preferred group of compounds of the invention is the compounds of formula I wherein R is R' (compounds Ia), whereby R' is:

R1 'NH(CH2)2 - wherein R1 ' is pyridinyl optionally mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro; or unsubstituted pyrimidinyl;

(C3-7)cycloalkyl optionally monosubstituted in 1-position with (C1-3)hydroxyalkyl;

R4 '(CH2)3 - wherein R4 ' is (C2-4)alkoxy; or

R5, wherein R5 is as defined above;

in free form or in acid addition salt form.

More preferred compounds of the invention are those compounds of formula I wherein R is R" (compounds Ib), whereby R" is:

R1 "NH(CH2)2 - wherein R1 " is pyridinyl mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;

(C4-6)cycloalkyl monosubstituted in 1-position with (C1-3)hydroxyalkyl;

R4 '(CH2)3 - wherein R4 ' is as defined above; or

R5 ' wherein R5 ' is a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety optionally mono- or plurisubstituted with (C1-8)alkyl; or adamantyl;

in free form or in acid addition salt form.

Even more preferred compounds of the invention are the compounds of formula I wherein R is R'" (compounds Ic), whereby R'" is:

R1 "NH(CH2)2 - wherein R1 " is as defined above;

(C4-6)cycloalkyl monosubstituted in 1-position with hydroxymethyl;

R4 '(CH2)3 - wherein R4 ' is as defined above; or

R5 " wherein R5 " is adamantyl;

in free form or in acid addition salt form.

A further group of compounds of the invention is compounds Ip, wherein R is Rp, which is:

a) R1 p NH(CH2)2 - wherein R1 p is a pyridinyl or pyrimidinyl moiety optionally mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;

b) (C3-7)cycloalkyl optionally monosubstituted in 1-position with (C1-3)hydroxyalkyl;

c) R2 p (CH2)2 - wherein R2 p is phenyl optionally mono- or independently di- or independently trisubstituted with halogen or (C1-3)alkoxy;

d) (R3 p)2 CH(CH2)2 - wherein each R3 p independently is phenyl optionally monosubstituted with halogen or (C1-3)alkoxy;

e) R4 (CH2)3 - wherein R4 is as defined above; or

f) isopropyl optionally monosubstituted in 1-position with (C1-3)hydroxyalkyl;

in free form or in pharmaceutically acceptable acid addition salt form.

A further group of compounds of the invention is compounds Is, wherein R is Rs, which is:

a) R1 s R1a s (CH2)ms - wherein R1 s is pyridinyl optionally mono- or independently disubstituted with chlorine, trifluoromethyl, cyano or nitro; pyrimidinyl optionally monosubstituted with chlorine or trifluoromethyl; or phenyl; R1a s is hydrogen or methyl; and ms is 2or3;

b) (C3-12)cycloalkyl optionally monosubstituted in 1-position with hydroxymethyl;

c) R2 s (CH2)ms - wherein either

R2 s is phenyl optionally mono- or independently di- or independently trisubstituted with halogen, alkoxy of 1 or 2 carbon atoms or phenylthio monosubstituted in the phenyl ring with hydroxymethyl; (C1-6)alkyl; 6,6-dimethylbicyclo[3.1.1]hept-2-yl; pyridinyl; naphthyl; cyclohexene; or adamantyl; and

ns is 1 to 3; or

R2 s is phenoxy; and ns is 2;

d) (3,3-diphenyl)propyl;

e) R4 s (CH2)ps wherein R4 s is 2-oxopyrrolidin-1 -yl or isopropoxy and ps is2or3;

f) isopropyl optionally monosubstituted in 1-position with hydroxymethyl;

g) R5 s wherein R5 s is: indanyl; a pyrrolidinyl or piperidinyl moiety optionally N-substituted with benzyl; bicyclo[2.2.1]hept-2-yl; 2,6,6trimethylbicyclo-[3.1.1]hept-3-yl; adamantyl; or (C1-8)alkyl1 optionally mono- or independently disubstituted with hydroxy, hydroxymethyl or phenyl;

in free form or in acid addition salt form.

The compounds of the invention may be prepared by a process which comprises coupling a reactive (2-cyanopyrrolidino)carbonylmethylene compound with an appropriate substituted amine; more particularly, for the preparation of the compounds of formula I it comprises reacting a compound of formula II ##STR3## wherein X is a reactive group, with a compound of formula III

NH.sub.2 R                                                 III

wherein R is as defined above,

and recovering the resultant compound of formula I in free form or in acid addition salt form.

X preferably is a halogen such as bromine, chlorine or iodine.

The process of the invention may be effected in conventional manner.

The compound of formula II is preferably reacted with at least 3 equivalents of a primary amine of formula III. The reaction is conveniently conducted in the presence of an inert, organic solvent, preferably a cyclic ether such as tetrahydrofuran. The temperature preferably is of from about 0° to about 35° C., preferably between about 0° and about 25° C.

The compounds of the invention may be isolated from the reaction mixture and purified in conventional manner, e.g. by chromatography.

The starting materials may also be prepared in conventional manner.

The compounds of formula II may e.g. be prepared by the following two-step reaction scheme: ##STR4##

Step 1 involves the reaction of the pyrrolidine of formula IV with a slight molar excess of a haloacetylhalide such as bromoacetylbromide or chloroacetylchloride and triethylamine and a catalytic amount of dimethylaminopyridine (DMAP). The reaction conveniently is conducted in the presence of an inert, organic solvent, preferably a chlorinated, aliphatic hydrocarbon such as methylene chloride, at a temperature of from about 0° to about 25° C., preferably at a temperature between about 0° and about 15° C.

Step 2 concerns the dehydration of the compound of formula V, prepared in Step 1, with at least 2 equivalents of trifluoroacetic anhydride (TFAA). The dehydration preferably is conducted in the presence of an inert, organic solvent such as tetrahydrofuran or a chlorinated, aliphatic hydrocarbon such as methylene chloride, at a temperature of from about 0° to about 25° C., preferably at a temperature between about 0° and about 15° C.

Insofar as its preparation is not particularly described herein, a compound used as starting material is known or may be prepared from known compounds in known manner or analogously to known methods or analogously to methods described in the Examples.

For example, the primary amine compounds of formula III are known and may be prepared by procedures documented in the literature. More particularly,: a) 1-hydroxymethylcyclopentylamine can be prepared by the reduction of 1-amino-1-cyclopentane carboxylic acid with lithium aluminum hydride as set forth below: ##STR5## The reduction is conducted in the presence of an inert, organic solvent, preferably a cyclic ether such as tetrahydrofuran, at the reflux temperature of the solvent for a period of between 14 and 24 hours. (b) 2-[(5-chloropyridin-2-yl)amino]ethylamine can be prepared by refluxing a mixture of 2,5-dichloropyridine with ethylenediamine in an oil bath for a period of between 6 and 12 hours. (c) Similarly, 2-[(5-trifluoromethylpyridin-2-yl)amino]ethylamine can be prepared by refluxing a mixture of 2-chloro-5-trifluoromethyl pyridine with ethylenediamine in an oil bath for a period of between 6 and 12 hours. (d) 2-[(5-cyanopyridin-2-yl)amino]-ethylamine can be prepared by stirring a mixture of 2-chloropyridine-5-carbonitrile and ethylenediamine at a temperature between 20° and 30° C., for a period of between 4 and 6 hours. (e) 2-[(pyrimidin-2-yl)amino]ethylamine can be prepared by adding ethylenediamine to ice-bath cooled 2-chloropyrimidine and allowing the mixture to react at a temperature between 20° and 30° C., for a period of between 12 and 20 hours. (f) 1-amino-1-cyclohexanemethanol can be prepared by the reduction of 1-amino-1-cyclohexane carboxylic acid with lithium aluminum hydride. The reduction is conducted in the presence of an inert, organic solvent, preferably a cyclic ether such as tetrahydrofuran, at the reflux temperature of the solvent for a period of between 14 and 24 hours. (g) 2(3-aminopropylamino)-5-cyanopyridine can be prepared by refluxing a mixture of 2,5-dichloropyridine with 1,3 propyl diamine in an oil bath for a period of between 6 and 12 hours. Alternatively, the above examples (a) through (g) may be carried out at room temperature.

The instant invention also includes pharmaceutical compositions useful in inhibiting DPP-IV comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable acid addition salt thereof.

In still another embodiment, the instant invention provides a method of inhibiting DPP-IV comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable acid addition salt thereof.

In a further embodiment, the instant invention provides a method of treating conditions mediated by DPP-IV inhibition comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of formula I above, or a pharmaceutically acceptable acid addition salt thereof.

As indicated above, all of the compounds of formula 1, and their corresponding pharmaceutically acceptable acid addition salts, are useful in inhibiting DPP-IV. The ability of the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, to inhibit DPP-IV may be demonstrated employing the Caco-2 DPP-IV Assay which measures the ability of test compounds to inhibit DPP-IV activity from human colonic carcinoma cell extracts. The human colonic carcinoma cell line Caco-2 was obtained from the American Type Culture Collection (ATCC HTB 37). Differentiation of the cells to induce DPP-IV expression was accomplished as described by Reisher, et al. in an article entitled "Increased expression of . . . intestinal cell line Caco-2" in Proc. Natl. Acad. Sci., Vol. 90, pgs. 5757-5761 (1993). Cell extract is prepared from cells solubilized in 10 mM Tris-HCl, 0.15 M NaCl, 0.04 t.i.u. aprotinin, 0.5% nonidet-P40, pH 8.0, which is centrifuged at 35,000 g for 30 min. at 4° C. to remove cell debris. The assay is conducted by adding 20 μg solubilized Caco-2 protein, diluted to a final volume of 125 pi in assay buffer (25 mM Tris-HCl pH 7.4, 140 mM NaCl, 10 mM KCl, 1% bovine serum albumin) to microtiter plate wells. The reaction is initiated by adding 25 μl of 1 mM substrate (H-Alanine-Proline-pNA; pNA is p-nitroaniline). The reaction is run at room temperature for 10 minutes after which time a 19 μl volume of 25% glacial acetic acid is added to stop the reaction. Test compounds are typically added as 30 μl additions and the assay buffer volume is reduced to 95 μl. A standard curve of free p-nitroaniline is generated using 0-500 μM solutions of free pNA in assay buffer. The curve generated is linear and is used for interpolation of substrate consumption (catalytic activity in nmoles substrate cleaved/min). The endpoint is determined by measuring absorbance at 405 nm in a Molecular Devices UV Max microfiter plate reader. The potency of the test compounds as DPP-IV inhibitors, expressed as IC-50, is calculated from 8-point, dose-response curves using a 4-parameter logistic function.

The following IC50 s were obtained:

______________________________________Compound     Caco-2 DPP-IV (nM)______________________________________Ex. 1        36  Ex. 2 176  Ex. 3 22  Ex. 4 140  Ex. 5 26  Ex. 6 50  Ex. 7A 165  Ex. 8 8  Ex. 7B 175  Ex. 9A 990  Ex. 7C 290  Ex. 9C 295  Ex. 10 54  Ex. 11 215  Ex. 7D 382  Ex. 7E 388  Ex. 12 279  Ex. 13 227  Ex. 14 110  Ex. 15 150  Ex. 16 130  Ex. 17 60  Ex. 18 100  Ex. 19 120  Ex. 20 90  Ex. 21 390  Ex. 22 150  Ex. 23 50  Ex. 24 70  Ex. 25 140  Ex. 26 170  Ex. 27 310  Ex. 28 90  Ex. 29 130  Ex. 30 650  Ex. 31 500  Ex. 32 150  Ex. 33 10  Ex. 34 37  Ex. 35 130  Ex. 36 160  Ex. 37 220  Ex. 38 50  Ex. 39 380  Ex. 40 240  Ex. 41 140  Ex. 42 240  Ex. 43 850  Ex. 44 5  Ex. 45 700  Ex. 46 150  Ex. 47 10  Ex. 48 35  Ex. 49 12  Ex. 50 23  Ex. 51 250  Ex. 52 20  Ex. 53 860  Ex. 54 240  Ex. 55 270  Ex. 56 350  Ex. 57 470  Ex. 58 50  Ex. 59 390  Ex. 60 600  Ex. 61 310  Ex. 62 270  Ex. 63 46  Ex. 64 220  Ex. 65 80  Ex. 66 60______________________________________

The ability of the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, to inhibit DPP-IV may also be demonstrated by measuring the effects of test compounds on DPP-IV activity in human and rat plasma employing a modified version of the assay described by Kubota, et al. in an article entitled "Involvement of dipeptidylpeptidase IV in an in vivo immune response" in Clin. Exp. Immunol., Vol. 89, pgs. 192-197 (1992). Briefly, five μl of plasma are added to 96-well flat-bottom mictotiter plates (Falcon), followed by the addition of 5 μl of 80 mM MgCl2 in incubation buffer (25 mM HEPES, 140 mM NaCl, 1% RIA-grade BSA, pH 7.8). After a 5 min. incubation at room temperature, the reaction is initiated by the addition of 10 μl of incubation buffer containing 0.1 mM substrate (H-Glycine-Proline-AMC; AMC is 7-amino4-methylcoumarin). The plates are covered with aluminum foil (or kept in the dark) and incubated at room temperature for 20 min. After the 20 min. reaction, fluorescence is measured using a CytoFluor 2350 fluorimeter (Excitation 380 nm Emission 460 nm; sensitivity setting 4). Test compounds are typically added as 2 μl additions and the assay buffer volume is reduced to 13 μl. A fluorescence-concentration curve of free AMC is generated using 0-50 μM solutions of AMC in assay buffer. The curve generated is linear and is used for interpolation of substrate consumption (catalytic activity in nmoles substrate cleaved/min). As with the previous assay, the potency of the test compounds as DPP-IV inhibitors, expressed as IC50, is calculated from 8-point, dose-response curves using a 4 parameter logistic function.

The following IC50 s were obtained:

______________________________________Compound human plasma DPP-IV (nM)                     rat plasma DPP-IV (nM)______________________________________Ex. 1    27               22  Ex. 3 7 6  Ex. 4 40 23  Ex. 5 37 18  Ex. 6 22 32  Ex. 8 12 11  Ex. 10 51 19  Ex. 12 95 38  Ex. 14 95 24  Ex. 15 70 40  Ex. 16 170 60  Ex. 17 250 120  Ex. 18 160 70  Ex. 19 180 50  Ex. 20 180 150  Ex. 21 210 110  Ex. 22 170 60  Ex. 23 40 40  Ex. 24 32 19  Ex. 25 110 140  Ex. 26 240 70  Ex. 27 150 160  Ex. 28 180 60  Ex. 29 28 9  Ex. 30 80 90  Ex. 31 80 100  Ex. 32 160 130  Ex. 33 20 10  Ex. 34 277 161  Ex. 35 1090 340  Ex. 36 170 80  Ex. 37 100 150  Ex. 38 65 23  Ex. 39 220 200  Ex. 40 340 370  Ex. 41 100 50  Ex. 42 140 180  Ex. 43 240 120  Ex. 44 10 10  Ex. 45 2130 390  Ex. 46 280 60  Ex. 47 11 5  Ex. 48 60 30  Ex. 49 8 3  Ex. 50 60 40  Ex. 51 180 150  Ex. 52 20 10  Ex. 53 490 400  Ex. 54 90 60  Ex. 55 140 90  Ex. 56 140 100  Ex. 57 420 150  Ex. 58 20 100  Ex. 59 280 130  Ex. 60 250 110  Ex. 61 260 80  Ex. 62 190 100  Ex. 63 60 30  Ex. 64 150 60  Ex. 65 90 40  Ex. 66 130 40______________________________________

In view of their ability to inhibit DPP-IV, the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, are useful in treating conditions mediated by DPP-IV inhibition. Based on the above and findings in the literature, it is expected that the compounds disclosed herein are useful in the treatment of conditions such as non-insulin-dependent diabetes mellitus, arthritis, obesity, allograft transplantation, and calcitonin-osteoporosis. More specifically, for example, the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, improve early insulin response to an oral glucose challenge and, therefore, are useful in treating non-insulin-dependent diabetes mellitus. The ability of the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, to improve early insulin response to an oral glucose challenge may be measured in insulin resistant rats according to the following method:

Male Sprague-Dawley rats that had been fed a high fat diet (saturated fat=57% calories) for 2-3 weeks were fasted for approximately 2 hours on the day of testing, divided into groups of 8-10, and dosed orally with 10 μmol/kg of the test compounds in CMC. An oral glucose bolus of lg/kg was administered 30 minutes after the test compound directly into the stomach of the test animals. Blood samples, obtained at various timepoints from chronic jugular vein catheters were analyzed for plasma glucose and immunoreactive insulin (IRI) concentrations, and plasma DPP-IV activity. Plasma insulin levels were assayed by a double antibody radioimmunoassay (RIA) method using a specific anti-rat insulin antibody from Linco Research (St. Louis, Mo.). The RIA has a lower limit of detection of 0.5 μU/ml with intra- and inter-assay variations of less than 5%. Data are expressed as % increase of the mean of the control animals. Upon oral administration, each of the compounds tested amplified the early insulin response which led to an improvement in glucose tolerance in the insulin resistant test animals. The following results were obtained:

______________________________________       Increase of Insulin Response  Compound at 10 μmol/kg______________________________________Ex. 1       61%  Ex. 3 66%  Ex. 5 108%  Ex. 8 144%  Ex. 12 59%______________________________________

The precise dosage of the compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, to be employed for treating conditions mediated by DPP-IV inhibition depends upon several factors, including the host, the nature and the severity of the condition being treated, the mode of administration and the particular compound employed. However, in general, conditions mediated by DPP-IV inhibition are effectively treated when a compound of formula I, or a corresponding pharmaceutically acceptable acid addition salt, is administered enterally, e.g., orally, or parenterally, e.g., intravenously, preferably orally, at a daily dosage of 0.002-5, preferably 0.02-2.5 mg/kg body weight or, for most larger primates, a daily dosage of 0.1-250, preferably 1-100 mg. A typical oral dosage unit is 0.01-0.75 mg/kg, one to three times a day.

Usually, a small dose is administered initially and the dosage is gradually increased until the optimal dosage for the host under treatment is determined. The upper limit of dosage is that imposed by side effects and can be determined by trial for the host being treated.

The compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, may be combined with one or more pharmaceutically acceptable carriers and, optionally, one or more other conventional pharmaceutical adjuvants and administered enterally, e.g., orally, in the form of tablets, capsules, caplets, etc. or parenterally, e.g., intravenously, in the form of sterile injectable solutions or suspensions. The enteral and parenteral compositions may be prepared by conventional means.

The compounds of formula I, and their corresponding pharmaceutically acceptable acid addition salts, may be formulated into enteral and parenteral pharmaceutical compositions containing an amount of the active substance that is effective for treating conditions mediated by DPP-IV inhibition, such compositions in unit dosage form and such compositions comprising a pharmaceutically acceptable carrier.

The compounds of formula I (including those of each of the subscopes thereof and each of the examples) may be administered in enantiomerically pure form (e.g., ee≧98%, preferably≧99%) or together with the R enantiomer, e.g., in racemic form. The above dosage ranges are based on the compounds of formula I (excluding the amount of the R enantiomer).

Prior US Provisional Application number 60/030,570, filed on Nov. 7, 1996 is incorporated by reference herein, in it's entirety.

The following examples show representative compounds encompassed by this invention and their synthesis. However, it should be clearly understood that they are for purposes of illustration only.

EXAMPLE 1 1-[2-[(5-chloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine dihydrochloride

A. Preparation of 2-carbamoylpyrrolidine-carbonylmethylene-(S)-bromide

22.37 g (196 mmol) of (S)-2-carbamoylpyrrolidine, 30.1 ml (216 mmol) of triethylamine and 30.0 mg of dimethylaminopyridine (DMAP) are dissolved in 200 ml of methylene chloride and the solution is then added, dropwise, to an ice-cold solution of 18.8 ml (216 mmol) of bromoacetylbromide in 192 ml of methylene chloride, over a period of 60 minutes under a calcium sulfate drying tube. The resultant solution is then stirred for 2 hours at ice-water temperature under a calcium sulfate dying tube, after which time it is poured into 3.5 liters of ethyl acetate. The resultant precipitate is filtered, washed with ethyl acetate, and the filtrate is concentrated to obtain the desired compound as a bard yellow taffy.

B. Preparation of 2-Cyanopyrrolidino-Carbonylmethylene-(S)Bromide

50.0 g (213 mmol) of the bromide compound prepared in a) above is dissolved in 300 ml of methylene chloride and the solution is cooled in an ice water bath under a calcium sulfate drying tube. The cooled solution is then poured into 60.2 ml (426 mmol) of trifluoroacetic anhydride over a 2 minute period and the resultant solution is then stirred at ice-water temperature under a calcium sulfate drying tube for 4 hours and partitioned between methylene chloride and saturated aqueous sodium bicarbonate. The product is then extracted into the methylene chloride layer and the aqueous layer is then washed twice with methylene chloride. The combined organic layers are then washed successively with water and brine and then dried over sodium sulfate. The solution is then filtered and the solvent is removed by rotovaping and high vacuum pumping to obtain the desired compound as a dark yellow solid.

C. Preparation of the Title Compound in Free Base Form

To a 500 ml flask is added 16.6g (97.2 mmol) of 2-[(5-chloropyridin-2-yl)amino]ethylamine and 100 ml of tetrahydrofuran and the mixture is cooled in an ice bath. To the cooled mixture is added 7.0 g (32.4 mmol) of the bromide compound prepared in b) above dissolved in 30 ml of tetrahydrofuran. The resultant mixture is stirred for 2 hours at 0° C., the solvent is removed by rotovaping and the mixture is partitioned between ethyl acetate and water. The product is then extracted into the ethyl acetate layer and the aqueous layer is then washed twice with ethyl acetate. The combined organic layers are then washed successively with water and brine, dried over sodium sulfate and concentrated to obtain the desired compound in crude form. The crude form is then purified on silica gel employing a mixture of 5% methanol in methylene chloride as the eluent to yield the desired compound as a light brown oil.

D. Preparation of the Title Compound

After dissolving the free base compound prepared in c) above in 30 ml of dry tetrahydrofuiran, hydrogen chloride gas is bubbled into the solution for five seconds. The off-white precipitate that forms is then filtered, washed with dry tetrahydrofuran and the solvent is removed by high vacuum pumping to obtain the title compound as an off-white solid, m.p. 265°-267° C.

EXAMPLE 2 1-[2-[(5-trifluoromethylpryrdin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine

To a 25 ml. flask is added 1.15 g (5.61 mmol) of 2-[(5-trifluoromethylpyrdin-2-yl)-amino]ethylamine and 10 ml of tetrahydrofuran and the mixture is cooled in an ice bath. To the cooled mixture is added 0.404 g (1.87 mmol) of the bromide compound of Example 1b) dissolved in 5 ml of tetrahydrofuran. The resultant mixture is stirred for 2 hours at 0° C., the solvent is removed by rotovaping and the mixture is partitioned between ethyl acetate and water. The product is then extracted into the ethyl acetate layer and the aqueous layer is then washed twice with ethyl acetate. The combined organic layers are then washed successively with water and brine, dried over sodium sulfate and concentrated to obtain the desired compound in crude form. The crude form is then purified on silica gel employing a mixture of 5% methanol in methylene chloride as the eluent to yield the title compound as a golden oil.

EXAMPLE 3 1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-S)-pyrrolidine dihydrochloride

A. Preparation of the Title Compound in Free Base Form

Following essentially the procedure of Example 1c), and using in place of the amine therein, an equivalent amount of 2-[(5-cyanopyridin-2-yl)amino]-ethylamine, the desired compound is obtained as a golden oil.

B. Preparation of the Title Compound

Following essentially the procedure of Example 1d), and using in place of the free base compound prepared in Example 1c), an equivalent amount of the free base compound prepared in a) above, the title compound is obtained as an off-white precipitate, m.p. 155°-157° C.

EXAMPLE 4 1[-2-[(pyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of 2-[(pyrimidin-2-yl)amino]ethylamine, and using in place of the eluent therein, a mixture of 10% methanol in methylene chloride, the title compound is obtained as a golden oil.

EXAMPLE 5 1-[(1 -hydroxymethylcyclopent-1-yl)amino]acetyl-2-cyano-(S)-pyrrolidine

To 1.5 g of (1-hydroxymethyl)cyclopentylamine in 40 ml of anhydrous tetrahydrofuran is added, dropwise via an addition funnel over 40 minutes, 0.93 g (4.35 mmol) of the bromide compound of Example 1b) under a calcium sulfate drying tube. The resultant mixture is then stirred at room temperature for 18 hours under a calcium sulfate drying tube, after which time hydrogen chloride gas is bubbled in for ˜5 seconds. The resultant gum is then separated from the solution by decanting and washed with 25 ml of tetrahydrofuran. The solution is then decanted and the gum is partitioned between methylene chloride and saturated aqueous sodium bicarbonate. The product is then extracted into the methylene chloride layer and the aqueous layer is then washed twice with methylene chloride. The combined organic layers are then washed successively with water and brine and then dried over sodium sulfate. The solution is then filtered and the solvent is removed by rotovaping and high vacuum pumping to obtain the title compound as a clear yellow oil which solidifies to a yellow solid, m.p. 65°-67° C.

EXAMPLE 6 1-[2-[(pyridin-2-yl)amino]ethylamino]acetyl-2-cyano(S)-pyrrolidine

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of 2-[(pyridin-2-yl)amino]ethylamine, and using in place of the eluent therein, a 90:10:0.5 mixture of methylene chloride, methanol and ammonium hydroxide, the title compound is obtained as a golden oil.

EXAMPLE 7

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of:

a) 2-[(4-chloropyrimidin-2-yl)amino]ethylamine;

b) 2-[(3-chloropyridin-2-yl)amino]ethylamine;

c) 2-[(4-trifluoromethylpyrimidin-2-yl)amino]ethylamine;

d) (2-chlorophenyl)ethylamine; and

e) (3,3-biphenyl)propylamine;

there is obtained:

A) 1-[2-[(4-chloropyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine as a tan solid;

B) 1-[2-[(3-chloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine as a golden oil;

C) 1-[2-[4-trifluoromethylpyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine as a golden oil;

D) 1-[(2-chlorophenyl)ethylamino]acetyl-2-cyano-(S)-pyrrolidine; and

E) 1-[(3,3-diphenyl)propylamino]acetyl-2-cyano-(S)-pyrrolidine, respectively.

EXAMPLE 8 1-[2-[(5-nitropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine

To 83.6 ml of anhydrous tetrahydrofuran is added 4.54 g (24.9 mmol) of 2-[(5-nitropyridin-2-yl)amino]ethylamine, and the resultant mixture is heated slightly then stirred at room temperature under a calcium sulfate drying tube. 1.80 g (8.3 mmol) of the bromide compound of Example 1b) in 20 ml of anhydrous tetrahydrofuran is then added, over a period of 30 minutes, under a calcium sulfate drying tube. The resultant mixture is then stirred at room temperature for 2 hours under a calcium sulfate drying tube and concentrated via rotovaping. The resultant paste is then partitioned between methylene chloride and saturated aqueous sodium bicarbonate. The product is then extracted into the methylene chloride layer and the aqueous layer is then washed twice with methylene chloride. The combined organic layers are then washed successively with water and brine and then dried over sodium sulfate. The solution is then filtered and the solvent is removed by rotovaping and high vacuum pumping to obtain the crude form of the title compound as a dark yellow-orange clear thick oil. The crude form is then flash chromatographed employing a mixture of 5% methanol in methylene chloride as the eluent to obtain the title compound as a bright yellow thick oil.

EXAMPLE 9

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of:

a) 2-[(3-chloro-5-trifluoromethylpyridin-2-yl)amino]ethylamine;

b) 2-[(3-trifluoromethylpyridin-2-yl)amino]ethylamine; and

c) 2-[(3,5-dichloropyridin-2-yl)amino]ethylamine;

and using in place of the eluent therein, a mixture of 3% methanol in methylene chloride, there is obtained:

A) 1-[2-[(3-chloro-5-trifluoromethylpyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine as a golden oil;

B) 1-[2-[(3-trifluoromethylpyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine as a golden oil; and

C) 1-[2-[(3,5-dichloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine as a golden oil.

EXAMPLE 10 1-[(cyclopent-1-yl)amino-acetyl-2-cyano-(S)-pyrrolidine monohydrochloride

A. Preparation of the Title Compound in Free Base Form

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of (cyclopent-1-yl)amine, the desired compound is obtained as a tan solid.

B. Preparation of the Title Compound

Following essentially the procedure of Example 1d), and using in place of the free base compound therein, an equivalent amount of the compound prepared in a) above, the title compound is obtained as a white solid.

EXAMPLE 11 1-[2-(2-bromo4,5-dimethoxyphenyl)ethylamino]acetyl-2-cyano-(S)-pyrrolidine

To 15 ml of anhydrous tetrahydrofuran is added 1.44 g (5.52 mmol) of 2-(2-bromo4,5-dimethoxy)ethylamine, and the resultant mixture is heated slightly under a calcium sulfate drying tube. 0.4 g (1.84 mmol) of the bromide compound of Example 1b) is then added, dropwise, over a period of 10 minutes. The resultant mixture is then stirred at room temperature for 18 hours under a calcium sulfate drying tube, concentrated via rotovaping and partitioned between methylene chloride and saturated aqueous sodium bicarbonate. The product is then extracted into the methylene chloride layer and the aqueous layer is then washed twice with methylene chloride. The combined organic layers are then washed successively with water and brine and then dried over sodium sulfate. The solution is then filtered and the solvent is removed by rotovaping and high vacuum pumping to obtain the crude form of the title compound as a clear yellow oil. The crude form is then flash chromatographed employing a mixture of 5% methanol in methylene chloride as the eluent to obtain the title compound as a clear, light yellow, thick oil.

EXAMPLE 12 1-[3-(isopropoxy)propylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride

A. Preparation of the Title Compound in Free Base Form

Following essentially the procedure of Example 1c), and using in place of the amine therein, an equivalent amount of 3-(isopropoxy)propylamine, the desired compound is obtained as a brown oil.

B. Preparation of the Title Compound

Following essentially the procedure of Example 1d), and using in place of the free base compound therein, an equivalent amount of the compound prepared in a) above, the title compound is obtained as a white solid, m.p. 174°-176° C.

EXAMPLE 13 1-1(2-hydroxy-1,1-dimethylethylamino)]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride

A. Preparation of the Title Compound in Free Base Form

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of 2-hydroxy-1,1 -dimethylethylamine, and using in place of the eluent therein, an 80:20:1 mixture of methylene chloride, methanol and ammonium hydroxide, the title compound is obtained as a golden oil.

B. Preparation of the Title Compound

Following essentially the procedure of Example 1d), and using in place of the free base compound therein, an equivalent amount of the compound prepared in a) above, the title compound is obtained as a brown solid.

EXAMPLE 14 1-[3-(2-oxo-pyrrolidin-1-yl)propylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride

A. Preparation of the Title Compound in Free Base Form

Following essentially the procedure of Example 2, and using in place of the amine therein, an equivalent amount of 3-(2-oxo-pyrrolidin-1-yl) propylamine, and using in place of the eluent therein, a 90:10:1 mixture of methylene chloride, methanol and ammonium hydroxide, the desired compound is obtained as a golden oil.

B. Preparation of the Title Compound

Following essentially the procedure of Example 1d), and using in place of the free base compound therein, an equivalent amount of the compound prepared in a) above, the title compound is obtained as a tan solid.

Below are the 13 C NMR signals for tie nitrile functionalities of the specific synthesized compounds described above:

______________________________________Compound # .sup.13 C NMR (MHz, solvent) δ ppm (CN)______________________________________Ex. 5      .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.64 ppm (CN)       Ex. 12 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 121.63 ppm      (CN)  Ex. 1 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 121.60 ppm (CN)       Ex. 3 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 120.42 ppm      (CN)  Ex. 8 .sup.13 C NMR (75 MHz, DMSO) δ 119.13 ppm (CN)  Ex. 7B .sup.13 C NMR (75 MHz, CDCl.sub.3) δ 118.23 ppm (CN)       Ex. 9A .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.68 ppm      (CN)  Ex. 9B .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.66 ppm (CN)       Ex. 9C .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.68 ppm      (CN)  Ex. 6 .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.84 ppm (CN)       Ex. 7C .sup.13 C NMR (75 MHz, CDCl.sub.3) δ 118.23 ppm      (CN)  Ex. 2 .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.68 ppm (CN)       Ex. 7A .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.66 ppm      (CN)  Ex. 4 .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.66 ppm (CN)       Ex. 10 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 121.69 ppm      (CN)  Ex. 11 .sup.13 C NMR (75 MHz, CDCl.sub.3) δ 118.31 ppm (CN)       Ex. 7D .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.63 ppm      (CN)  Ex. 7E .sup.13 C NMR (75 MHz, CD.sub.3 OD) δ 119.64 ppm (CN)       Ex. 13 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 121.52 ppm      (CN)  Ex. 14 .sup.13 C NMR (75 MHz, D.sub.2 O) δ 121.52 ppm (CN)______________________________________
EXAMPLE 15 1-[(1-hydroxymethylcylohexyl)amino]acetyl-2-cyano-(S)-pyrrolidine ##STR6## A. Preparation of 1-chloroacetyl-2-cyanopyrrolidine

To a mechanically stirred solution of 20.0 g (180.0 mmol) of chloroacetylchloride and 97 g (0.70 mmol) of potassium carbonate in 150 ml of tetrahydrofuran was added a solution of L-prolinamide 20.0 g (180.0 mmol) in 500 ml of tetrahydrofuran in a dropwise fashion over 45 minutes. This reaction was then mechanically stirred for an additional two hours. The reaction was then filtered to remove potassium salts and the filtrate was dried over Na2 SO4. The Na2 SO4 was then removed via filtration and to this colorless filtrate was added trifluoroacetic anhydride (25.0 ml, 0.180 mmol) in one portion. The reaction is then magnetically stirred for 1 hour and the resulting clear yellow/orange solution is concentrated via rotovap. The excess trifluoroacetic anhydride is chased by adding ethyl acetate to the concentrated oil and reconcentrating via rotovap. This operation is performed three times.

The resulting oil is partitioned between ethyl acetate and water. The product is then extracted into the ethyl acetate and the aqueous layer is then washed twice with ethyl acetate. The combined organic layers are then washed successively with water and brine dried over magnesium sulfate, filtered and concentrated to obtain 17.0 g (98.6 mmol) of 1-chloroacetyl-2-cyanopyrrolidine as a yellow solid.

B. Preparation of the Title Compound

To a 100 ml flask is dissolved 1.2 g (8.70 mmol) of 1-amino-1-cyclohexanemethanol (amine nucleophile; preparation described above) into 20 ml of tetydrofuran. Potassium carbonate (1.60 g, 11.6 mmol) is then added and the solution is cooled in an ice-water bath. To this cooled mixture is added a solution of 0.50 g (2.89 mmol) of 1 -chloroacetyl-2-cyanopyrrolidine in 10 ml of tetrahydrofuran over 20 minutes. The reaction is then stirred at ice-water temperature for two hours under a calcium sulfate drying tube and then allowed to stir at room temperature for 18 hours. The reaction is then filtered with THF washing to remove the potassium salts and concentrated via rotovap to provide an opaque, light-yellow oil. The crude form is then purified on silica gel employing a mixture of 5% methanol in methylene chloride as the eluent to yield the free base of the title compound as a yellow waxy solid. Melting point=softens at 93° C. 13 C NMR(ppm)=118.1.

Using the procedures described in the above examples, and/or with minor modifications thereto as noted below, the following additional compounds were prepared:

EXAMPLE 16

Pyrrolidine, 1-[[2-(4-ethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR7##

4-Ethoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=182°-184° C. 13 C NMR (ppm)=121.4.

EXAMPLE 17 Pyrrolidine, 1-[(1-phenylmethyl-3-pyrrolidinyl)amino]acetyl-2-cyano-,(S)-(R)-,dihydrochloride ##STR8##

(3R)-(-)-1-Benzyl-3-aminopyrrolidine (commercially available) was used as the amine nucleophile. The title compound was an off white solid. Melting point=175° C.-177° C. 13 C NMR (ppm)=121.5.

EXAMPLE 18 Pyrrolidine, 1-[[2-(4-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR9##

4-Methoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=185° C.-187° C. 13 C NMR (ppm)=121.4.

EXAMPLE 19

Pyrrolidine, 1-[[2-(3-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR10##

3-Methoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was a light yellow solid. Melting point=172° C.-174° C. 13 C NMR (ppm)=119.25.

EXAMPLE 20 Pyrrolidine, 1-[[(1-naphthalenyl)methyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR11##

1-Naphthalenemethylamine (commercially available) was used as the amine nucleophile. The title compound was a light yellow solid. Melting point=130° C.-135° C. 13 C NMR (ppm)=119.29.

EXAMPLE 21 Pyrrolidine, 1-[(3-phenylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR12##

3-Phenyl-1-propylamine (commercially available) was used as the amine nucleophile. The title compound was an off-white fluffy solid. 13 C NMR (ppm)=119.26.

EXAMPLE 22 Pyrrolidine, 1-[[3-[(phenyl)(methyl)amino]propyl]amino]acetyl-2-cyano-, (S)-,dihydrochloride ##STR13##

N-(3-Aminopropyl)-N-methylaniline (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=96° C.-98° C. (foams). 13 C NMR (ppm)-121.6.

EXAMPLE 23 Pyrrolidine, 1-[2-[(3,4-dimethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR14##

3,4-Dimethoxyphenethylamine (commercially available) was used as the amine nucleophile. The Title compound was a white solid. Melting point=170° C.-172° C. 13 C NMR (ppm)=121.5.

EXAMPLE 24 Pyrrolidine, 1-(acycloheptylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR15##

Cycloheptylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=68° C.-70° C. 13 C NMR (ppm)=121.4.

EXAMPLE 25 Pyrrolidine, 1-[[(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]amino]acetyl-2-cyano-[1S[1α,2α(S*),5α]]-(S)-,monohydrochloride ##STR16##

(-)-Cis-myrtanylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=275° C.-279° C., decomposed. 13 C NMR (ppm)=119.17.

EXAMPLE 26 Pyrrolidine, 1-[[2-(2,5-dmethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR17##

2,5-Dimethoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=65° C.-67° C. 13 C NMR(ppm)=119.25.

EXAMPLE 27 Pyrrolidine, 1-[[2-(1-cyclohexen-1-yl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochlorid ##STR18##

2-(1-Cyclohexenyl) ethylamine (commercially available) was used as the amine nucleophile. The title compound was an off-white fluffy solid. Melting point=162° C.-164° C. 13 C NMR (ppm)=119.27.

EXAMPLE 28 Pyrrolidine, 1-(cyclohexylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR19##

Cyclohexylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=182° C.-184° C. 13 C NMR (ppm)=119.28.

EXAMPLE 29

Pyrrolidine, 1-[(bicyclo[2.2.1]hept-2-yl)amino]acetyl-2-cyano-[1S[1α,2α(S*),5α]]-(S)-,monohydrochloride ##STR20##

(±)-Exo-2-aminonorbornane (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=98° C.-100° C. 13 C NMR (ppm)=118.36.

EXAMPLE 30 Pyrrolidine, 1-[[2-(2-pyridinyl)ethyl]amino]acetyl-2-cyano-, (S)-,dihydrochloride ##STR21##

2-(2-Aminoethyl) pyridine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=95° C.-97° C. 13 C NMR (ppm)=121.5.

EXAMPLE 31 Pyrrolidine, 1-[[(2-phenylamino)ethyl]amino]acetyl-2-cyano-,(S)-,dihydrochloride ##STR22##

N-phenylethylenediamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=124° C.-126° C. 13 C NMR (ppm)=121.4.

EXAMPLE 32 Pyrrolidine, 1-[(3,3-dimethylbutyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR23##

3,3-Dimethylbutylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=164° C.-166° C. 13 C NMR (ppm)=121.5.

EXAMPLE 33

Pyrrolidine,1-[(2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)amino]acetyl-2-cyano-, (S)[1S [1α,2β,3α(S*),5α]]-monohydrochloride ##STR24##

(1R,2R,3R,5S)-(-)-Isopinocampheylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=82° C.--84° C. 13 C NMR (ppm)=121.5.

EXAMPLE 34 Pyrrolidine, 1-[[(1-hydroxymethyl)propyl]amino]acetyl-2-cyano-[S,S)]- ##STR25##

(S)-(+)-2-Amino-1-butanol (commercially available) was used as the amine nucleophile. The title compound was used as an off-white solid. Melting point=80° C.-82° C. 13 C NMR (ppm)=118.2.

EXAMPLE 35 Pyrrolidine, 1-[[[2-[(2-hydroxymethyl)phenyl]thio]phenylmethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR26##

2-(2-(Aminomethyl) phenylthio) benzyl alcohol (commercially available) was used as the amine nucleophile. The title compound was a yellow solid. Melting point=65° C.-67° C. 13 C NMR (ppm)=121.4.

EXAMPLE 36 Pyrrolidine, 1-[[2-(2-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR27##

2-Methoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was an off white solid. Melting point=174° C. -176° C. 13 C NMR (ppm)=121.7.

EXAMPLE 37 Pyrrolidine, 1-[(5-hydroxypentyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR28##

5-Amino-1-pentanol (commercially available) was used as the amine nucleophile. The title compound was a sticky light-green solid. 13 C NME (ppm)=121.67.

EXAMPLE 38 Pyrrolidine, 1-(cyclobutylamino)acetyl-2-cyano-,(S)-monohydrochloride ##STR29##

Cyclobutylamine (commercially available) was used as the amine nucleophile. The title compound was an off-white solid. Melting point=274° C.-278° C. decomposed. 13 C NMR (ppm)=121.64.

EXAMPLE 39 Pyrrolidine, 1-[[2-(2,4-dichlorophenyl)ethyl]amino]acetyl-2-cyano-,(S),monohydrochloride ##STR30##

2,4-Dichlorophenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=154° C.-156° C. 13 C NMR (ppm)=121.48.

EXAMPLE 40 Pyrrolidine, 1-[(1-hydroxymethyl]-3-methylbutyl)amino]acetyl-2-cyano-,O-,(S)-, ##STR31##

(S)-(+)-Leucinol (commercially available) was used as the amine nucleophile. The title compound was a light yellow solid. Melting point=65° C.-66° C. 13 C NMR (ppm)=117.99.

EXAMPLE 41 Pyrrolidine, 1-[(2-hydroxy-2-phenylethyl)amino]acetyl-2-cyano-[2S-[1R*,2S*]-monohydrochloride ##STR32##

(1R,2S)-(-)-Norephedrine (commercially available) was used as the amine nucleophile. The title compound was a light yellow solid. Melting point=82° C.-83° C. 13 C NMR (ppm)=118.35.

EXAMPLE 42 Pyrrolidine, 1-[[2-(2-fluorophenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR33##

2-Fluorophenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=160° C.-162° C. 13 C NMR (ppm)=121.70.

EXAMPLE 43

Pyrrolidine, 1-(cyclopropylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR34##

Cyclopropylamine (commercially available) was used as the amine nucleophile. The title compound was an off-white solid. Melting point=170° C.-172° C. 13 C NMR (ppm)=121.62.

EXAMPLE 44 Pyrrolidine, 1-[(2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)amino]acetyl-2-cyano-,[1S[1.alpha.,2α,3β(S*),5α]]-monohydrochloride ##STR35##

(1S,2S,3S,5R)-(+)-Isopinocampheylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=84° C.-86° C. 13 C NMR (ppm)=121.8.

EXAMPLE 45 Pyrrolidine, 1-[[(2-phenoxy)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR36##

2-Phenoxyethylamine (commercially available) was used as the amine nucleophile. The title compound was a sticky golden solid. 13 C NMR (ppm)=121.7.

EXAMPLE 46 Pyrrolidine, 1-[2-[(3,5-dimethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR37##

3,5-Dimethoxyphenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=74° C.-76° C. 13 C NMR (ppm)=121.66.

EXAMPLE 47 Pyrrolidine, 1-[(1-adamantyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR38##

1-Adamantanamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=240° C.-242° C. 13 C NMR (ppm)=121.80.

EXAMPLE 48 Pyrrolidine, 1-[(1,1,3,3-tetramethylbutyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR39##

1,1,3,3-Tetramethylbutylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=68° C.-70° C. 13 C NMR (ppm)=121.55.

EXAMPLE 49 Pyrrolidine, 1-[(2-adamantyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR40##

2-Adamantanamine (commercially available) was used as the amine nucleophile. The title compound was an off-white fluffy solid. Melting point=122° C.-124° C. 13 C NMR=(ppm)=121.69.

EXAMPLE 50 Pyrrolidine, 1-[(1,1-dimethylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR41##

1,1-Dimethylpropylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. Melting point=62° C.-64° C. 13 C NMR (ppm)=121.53.

EXAMPLE 51 Pyrrolidine, 1-[(phenylmethyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR42##

Benzylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=58° C.-60° C. 13 C NMR (ppm)=121.38.

EXAMPLE 52 Pyrrolidine, 1-[(1,1-dimethylethyl)amino]acetyl-2-cyano-,(S),monohydrochloride ##STR43##

Tert-butylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=226° C.-228° C. 13 C NMR ppm)=121.56.

EXAMPLE 53 Pyrrolidine, 1-[[(2-adamantyl)methyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR44##

1-Adamnantanemethylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=158° C.-160° C. 13 C NMR=121.56.

EXAMPLE 54 Pyrrolidine, 1-[(2-phenylethyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR45##

Phenethylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=275° C.-280° C. decomposed. 13 C NMR (ppm)=121.52.

EXAMPLE 55 Pyrrolidine, 1-(pentylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR46##

Pentylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point 176° C.-178° C. 13 C NMR (ppm)=121.67.

EXAMPLE 56 Pyrrolidine, 1-(butylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR47##

Butylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=180° C.-182° C. 13 C NMR (ppm)=121.56.

EXAMPLE 57 Pyrrolidine, 1-(cyclododecylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR48##

Cyclododecylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. 13 C NMR (ppm)=121.52.

EXAMPLE 58 Pyrrolidine, 1-(cyclooctylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR49##

Cyclooctylamine (commercially available) was used as the amine nucleophile. The title compound was a white fluffy solid. 13 C NMR (ppm)=121.64.

EXAMPLE 59 Pyrrolidine, 1-(propylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR50##

Propylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=193° C.-194° C. 13 C NMR (ppm)=121.57.

EXAMPLE 60 Pyrrolidine, 1-(ethylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR51##

Ethylamine (commercially available) was used as the amine nucleophile. The title compound was an off-white stick solid. 13 C NMR (ppm)=121.67.

EXAMPLE 61 Pyrrolidine, 1-(heptylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR52##

Heptylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=170° C.-172° C. 13 C NMR (ppm)=121.7.

EXAMPLE 62 Pyrrolidine, 1-(hexylamino)acetyl-2-cyano-,(S)-,monohydrochloride ##STR53##

Hexylamine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=174° C.-176° C. 13 C NMR (ppm)=121.75.

EXAMPLE 63 Pyrrolidine, 1-[[3-[(5-cyano-2-pyridinyl)amino]propyl]amino]acetyl-2-cyano-,(S)-, dihydrochloride ##STR54##

2(3-Aminopropylamino)-5-cyanopyridine (preparation described above) was used as the amine nucleophile. The title compound was a white sticky solid. Melting point=210° C.-212° C. 1 C NMR(pm)=119.33.

EXAMPLE 64 Pyrrolidine, 1-[(1-ethylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR55##

3-Aminopentane (commercially available) was used as the amine nucleophile. The title compound was a white fluffy sticky solid. 13 C NMR ppm)=119.35.

EXAMPLE 65 Pyrrolidine, 1-[(2,3-dihydro-1H-inden-2-yl)amino]acetyl-2-cyano-,(S)-,monohydrochloride ##STR56##

2-Aminoindan (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=182° C.-184° C. 13 C NMR (ppm)=121.38.

EXAMPLE 66 Pyrrolidine, 1-[(1-phenylmethyl-4-piperidinyl)amino]acetyl-2-cyano-,(S)-,-monohydrochloride ##STR57##

4-Amino-1-benzylpiperidine (commercially available) was used as the amine nucleophile. The title compound was a white solid. Melting point=280° C.-283° C. decomposed. 13 C NMR (ppm)=121.39.

Claims (11)

What is claimed is:
1. A compound of formula I: ##STR58## wherein R is a group .paren open-st.CH2 .paren close-st.m N--R1 ; an unsubstituted (C3-12)-cycloaklyl ring; a (C3-12)cycloalkyl ring substituted in the 1-position by a hydroxy(C1-3)alkyl group; a group .paren open-st.CH2 .paren close-st.n R2 ; a group ##STR59## a group .paren open-st.CH2 .paren close-st.p R4 ; an isopropyl group; an isopropyl group substituted in the i-position by a hydroxy(C1-3)alkyl group; or R5 ;
R1 is an unsubstituted pyridine ring; a pyridine ring mono- or di-substituted by halo, trifluoromethyl, cyano or nitro; an unsubstituted pyrimidine ring; a pyrimidine ring monosubstituted by halo, trifluoromethyl, cyano or nitro; or an unsubstituted phenyl ring;
R2 is an unsubstituted phenyl ring; a phenyl ring mono-, di- or tri-substituted by halo, (C1-3)alkoxy or a phenyl sulfide (optionally substituted with a (C1-8)alkoxy); phenoxy; (C1-8)alkyl; 3,1,1 bicyclic ring system (optionally substituted with 1 or more (C1-8) alkyl groups); unsubstituted pyridine ring; naphthyl, cyclohexene; or adamantyl;
each R3, independently, is an unsubstituted phenyl ring; or a phenyl ring mono-substituted by halo or (C1-3)alkoxy;
R4 is a 2-oxopyrrolidine group or a (C2-4)alkoxy group;
R5 is indan; pyrrolidine (unsubstituted or substituted with --CH2 -phenyl); piperidine (unsubstituted or substituted with --CH2 -phenyl); a 2.2,1 bicyclic ring system (unsubstituted or substituted with 1 or more (C1-8) alkyl groups); adamantyl; a straight or branched chain (C1-8) alkyl (unsubstituted or substituted by one or more substituents selected from hydroxy, --CH2 OH and phenyl); or a 3,1,1 bicyclic ring system (unsubstituted or substituted with 1 or more (C1-8)alkyl groups); and
m and n independently are integers of 1 to 3;
p is an integer of 2 to 4;
or a pharmaceutically acceptable acid addition salt thereof.
2. A compound according to claim 1 of formula Ia: ##STR60## where R' is a group .paren open-st.CH2 .paren close-st.N--R1 '; an unsubstituted (C3-7)cycloalkyl ring; a (C3-7) cycloalkyl ring substituted in the 1-position by a hydroxy(C1-3)alkyl group; a group .paren open-st.CH2 .paren close-st.3 R4 '; or a group R5 as defined in claim 1;
R1 ' is an unsubstituted pyridine ring; a pyridine ring mono- or di-substituted by halo, trifluoromethyl, cyano or nitro; or an unsubstituted pyrimidine ring; and
R4 ' is a (C2-4)alkoxy group;
or a pharmaceutically acceptable acid addition salt thereof.
3. A compound according to claim 2 of formula Ib: ##STR61## where R" is a group .paren open-st.CH2 .paren close-st.2 N--R1 "; a (C4-6)cycloalkyl ring substituted in the 1-position by a hydroxy(C1-3)alkyl group; a group CH2 .paren close-st.3 R4 '; or a group R5 ';
R1 " is a pyridine ring mono- or di-substituted by halo, trifluoromethyl, cyano or nitro;
R4 ' is as defined in claim 2; and
R5 ' is a 3,1,1 bicyclic ring system (unsubstituted or substituted with 1 or more (C1-8) alkyl groups; a 2,2,1 bicyclic ring system (optionally substituted with 1 or more (C1-8) alkyl groups; or adamantyl;
or a pharmaceutically acceptable acid addition salt thereof.
4. A compound according to claim 3 of formula Ic: ##STR62## where R'" is a group .paren open-st.CH2 .paren close-st.2 N--R1 '" ; a (C4-6)cycloalkly ring substituted in the 1-position by a hydroxymethyl group; a group .paren open-st.CH2 .paren close-st.3 R4 "; or a group R5 ";
R1 '" is a pyridine ring monosubstituted by halo, trifluoromethyl, cyano or nitro;
R4 ' is as defined in claim 3; and
R5 &41 is adamantyl;
or a pharmaceutically acceptable acid addition salt thereof.
5. A compound of formula I: ##STR63## wherein R is: a) R1 R1a N(CH2)m - wherein
R1 is a pyridinyl or pyrimidinyl moiety unsubstituted or mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy, halogen, trifluoromethyl, cyano or nitro; or phenyl unsubstituted or- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;
R2a is hydrogen or (C1-8 alkyl; and
m is 2 or3;
b) (C3-12)cycloalkyl unsubstituted or monosubstituted in the 1-position with (C1-3)hydroxyalkyl;
c) R2 (CH2)n - wherein either
R2 is phenyl unsubstituted or mono- or independently di- or independently trisubstituted with (C1-4)alkyl, (C1-4)alkoxy, halogen or phenylthio unsubstituted or monosubstituted in the phenyl ring with hydroxymethyl; or is (C1-8)alkyl; a [3.1.1]bicyclic carbocyclic moiety unsubstituted or mono- or plurisubstituted with (C1-8)alkyl; a pyridinyl or naphthyl moiety unsubstituted or mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen; cyclohexene; or adamantyl; and
n is 1 to 3; or
R2 is phenoxy unsubstituted or mono- or independently disubstituted with (C1-4), (C1-4)alkoxy or halogen; and
n is 2or3;
d) (R3)2 CH(CH2)2 - wherein each R3 independently is phenyl unsubstituted or mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;
e) R4 (CH2)p - wherein R4 is 2-oxopyrrolidinyl or (C2-4)alkoxy and p is2to4;
f) isopropyl unsubstituted or monosubstituted in the 1 -position with (C1-3)hydroxyalkyl;
g) R5 wherein R5 is: indanyl; a pyrrolidinyl or piperidinyl moiety unsubstituted or substituted with benzyl; a [2.2.1]- or [3.1.1]bicyclic carbocyclic moiety unsubstituted or mono- or plurisubstituted with (C1-8)alkyl; adamantyl; or (C1-8)alkyl unsubstituted or mono- or independently plurisubstituted with hydroxy, hydroxymethyl or phenyl unsubstituted or mono- or independently disubstituted with (C1-4)alkyl, (C1-4)alkoxy or halogen;
in free form or in acid addition salt form.
6. A compound according to claim 5 (a compound Ip) wherein R is Rp, which is:
a) R1 p NH(CH2)2 - wherein R1 p is a pyridinyl or pyrimidinyl moiety unsubstituted or mono- or independently disubstituted with halogen, trifluoromethyl, cyano or nitro;
b) (C3-7)cycloalkyl unsubstituted or the monosubstituted in 1-position with (C1-3)hydroxyalkyl;
c) R2 p (CH2)2 - wherein R2 p is phenyl unsubstituted or mono- or independently di- or independently trisubstituted with halogen or (C1-3)alkoxy;
d) (R3 p)2 CH(CH2)2 - wherein each R3 p independently is phenyl substituted or monosubstituted with halogen or (C1-3)alkoxy;
e) R4 (CH2)3 - wherein R4 is as defined in claim 5; or
f) isopropyl unsubstituted or monosubstituted in 1-position with (C1-3)hydroxyalkyl;
in free form or in acid addition salt form.
7. A compound according to claim 5 (a compound Is), wherein R is Rs, which is:
a) R1 s R1a s (CH2)ms - wherein R1 s is pyridinyl unsubstituted or mono- or independently disubstituted with chlorine, trifluoromethyl, cyano or nitro; pyrimidinyl unsubstituted or monosubstituted with chlorine or trifluoromethyl; or phenyl; R1a s is hydrogen or methyl; and ms is2or3;
b) (C3-12)cycloalkyl unsubstituted or monosubstituted in the 1-position with hydroxymethyl;
c) R2 s (CH2)ns - wherein either R2 s is phenyl unsubstituted or mono- or independently di- or independently trisubstituted with halogen, alkoxy of 1 or 2 carbon atoms or phenylthio monosubstituted in the phenyl ring with hydroxymethyl; (C1-6)alkyl; 6,6-dimethylbicyclo[3.1.1]hept-2-yl; pyridinyl; naphthyl; cyclohexene; or adamantyl; and ns is 1 to 3; or R2 s is phenoxy; and ns is 2;
d) (3,3-diphenyl)propyl;
e) R4 s (CH2)ps wherein R4 s is 2-oxopyrrolidin-1-yl or isopropoxy and ps is2or3;
f) isopropyl unsubstituted or monosubstituted in 1-position with hydroxymethyl;
g) R5 s wherein R5 s is: indanyl; a pyrrolidinyl or piperidinyl moiety unsubstituted or N-substituted with benzyl; bicyclo[2.2.1]hept-2-yl; 2,6,6-trimethylbicyclo-[3.1.1]hept-3-yl; adamantyl; or (C1-8)alkyl optionally mono- or independently disubstituted with hydroxy, hydroxymethyl or phenyl;
in free form or in acid addition salt form.
8. The compound according to claim 5 wherein R is 2-[(5-cyanopyridin-2-yl)amino]ethyl, i.e. 1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine, in free form or in acid addition salt form, or a compound according to claim 5 which is of formula I wherein R is either
2-[(5-chloropyridin-2-yl)amino]ethyl, or
(1-hydroxymethyl)cyclopent-1-yl, or
2-[(5-nitropyridin-2-yl)amino]ethyl, or
3-(isopropoxy)propyl,
in free form or in acid addition salt form.
9. A compound according to claim 5 which is:
1-[2-[(5-chloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine dihydrochloride;
1-[2-[(5-trifluoromethylpryridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(5-cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine dihydrochloride;
1-[2-[(pyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[(1-hydroxymethylcyclopent-1-yl)amino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(pyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(4-chloropyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(3-chloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[4-trifluoromethylpyrimidin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[(2-chlorophenyl)ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[(3,3-diphenyl)propylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(5-nitropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine;
1-[2-[(3-chloro-5-trifluoromethylpyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[2-[(3-trifluoromethylpyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)pyrrolidine;
1-[2-[(3,5-dichloropyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[(cyclopent-1-yl)amino-acetyl-2-cyano-(S)-pyrrolidine monohydrochloride;
1-[2-(2-bromo-4,5-dimethoxyphenyl)ethylamino]acetyl-2-cyano-(S)-pyrrolidine;
1-[3-(isopropoxy)propylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride;
1-[(2-hydroxy-1,1-dimethylethylamino)]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride;
1-[3-(2-oxo-pyrrolidin-1-yl)propylamino]acetyl-2-cyano-(S)-pyrrolidine monohydrochloride;
1-[(1-hydroxymethylcylohexyl)amino]acetyl-2-cyano-(S)-pyrrolidine;
Pyrrolidine, 1-[[2-(4-ethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1-phenylmethyl-3-pyrrolidinyl)amino]acetyl-2-cyano-,(S)-(R)-,dihydrochloride;
Pyrrolidine, 1-[[2-(4-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 3-[[2-(3-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[(1-naphthalenyl)methyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(3-phenylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[3-[(phenyl)(methyl)amino]propyl]amino]acetyl-2-cyano-,(S)-,dihydrochloride;
Pyrrolidine, 1-[2-[(3,4-dimethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(acycloheptylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[(6,6-dimethylbicyclo[3.1.1]hept-2-yl)methyl]amino]acetyl-2-cyano-[1S[1α,2α(S*),5α]]-(S)-,monohydrochloride;
Pyrrolidine, 1-[[2-(2,5-dmethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[2-(1-cyclohexen-1-yl)ethyl]amino]acetyl-2-cyano-,(S)-;
Pyrrolidine, 1-(cyclohexylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(bicyclo[2.2.1]hept-2-yl)amino]acetyl-2-cyano-[1S[1α,2α(S*),5α]]-(S)-,monohydrochloride;
Pyrrolidine, 1-[[2-(2-pyridinyl)ethyl]amino]acetyl-2-cyano-,(S)-,dihydrochloride;
Pyrrolidine, 1-[[(2-phenylamino)ethyl]amino]acetyl-2-cyano-,(S)-,dihydrochloride;
Pyrrolidine, 1-[(3,3-dimethylbutyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(2,6,6-trimethylbicyclo[3.1.1 ]hept-3-yl)amino]acetyl-2-cyano-,(S)[1S[1α,2β,3α(S*),5.alpha.]]-monohydrochloride;
Pyrrolidine, 1-[[(1 -hydroxymethyl)propyl]amino]acetyl-2-cyano-[S,S)]-;
Pyrrolidine, 1-[[[2-[(2-hydroxymethyl)phenyl]thio]phenylmethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[2-(2-methoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(5-hydroxypentyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(cyclobutylamino)acetyl-2-cyano-,(S)-monohydrochloride;
Pyrrolidine, 1-[[2-(2,4dichlorophenyl)ethyl]amino]acetyl-2-cyano-,(S),monohydrochloride;
Pyrrolidine, 1-[(1-hydroxymethyl]-3-methylbutyl)amino]acetyl-2-cyano-,O-,(S)-,;
Pyrrolidine, 1-[(2-hydroxy-2-phenylethyl)amino]acetyl-2-cyano-[2S-[1R*,2S*]-monohydrochloride;
Pyrrolidine, 1-[[2-(2-fluorophenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(cyclopropylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(2,6,6-trimethylbicyclo[3.1.1]hept-3-yl)amino]acetyl-2-cyano-[1S[1.alpha.,2α,3β(S*),5α]]-monohydrochloride;
Pyrrolidine, 1-[[(2-phenoxy)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[2-[(3,5-dimethoxyphenyl)ethyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1 -adamantyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1,1,3,3-tetramethylbutyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(2-adamantyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1,1-dimethylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(phenylmethyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1,1 -dimethylethyl)amino]acetyl-2-cyano-,(S),monohydrochloride;
Pyrrolidine, 1-[[(2-adamantyl)methyl]amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(2-phenylethyl)amino]acetyl-2-cyano-, (S)-, monohydrochloride;
Pyrrolidine, 1-(pentylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(butylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(cyclododecylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(cyclooctylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(propylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(ethylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(heptylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-(hexylamino)acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[[3-[(5-cyano-2-pyridinyl)amino]propyl]amino]acetyl-2-cyano-,(S)-,dihydrochloride;
Pyrrolidine, 1-[(1-ethylpropyl)amino]acetyl-2-cyano-,(S)-,monohydrochloride,
Pyrrolidine, 1-1(2,3-dihydro-1H-inden-2-yl)amino]acetyl-2-cyano-,(S)-,monohydrochloride;
Pyrrolidine, 1-[(1-phenylmethyl-4-piperidinyl)amino]acetyl-2-cyano-,(S)-,
monohydrochloride; or a pharmaceutically acceptable salt of any of the above compounds which are in free form.
10. A pharmaceutical composition comprising a compound according to claim 5 in free form or in pharmaceutically acceptable acid addition salt form, together with at least one pharmaceutically acceptable carrier or diluent.
11. A compound according to claim 8 which is 1-[2-[(5cyanopyridin-2-yl)amino]ethylamino]acetyl-2-cyano-(S)-pyrrolidine dihydrochloride.
US08962168 1996-11-07 1997-10-31 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV Expired - Lifetime US6011155A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US3057096 true 1996-11-07 1996-11-07
US08962168 US6011155A (en) 1996-11-07 1997-10-31 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08962168 US6011155A (en) 1996-11-07 1997-10-31 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US09428224 US6124305A (en) 1996-11-07 1999-10-20 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09428224 Division US6124305A (en) 1996-11-07 1999-10-20 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV

Publications (1)

Publication Number Publication Date
US6011155A true US6011155A (en) 2000-01-04

Family

ID=26706181

Family Applications (2)

Application Number Title Priority Date Filing Date
US08962168 Expired - Lifetime US6011155A (en) 1996-11-07 1997-10-31 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US09428224 Expired - Lifetime US6124305A (en) 1996-11-07 1999-10-20 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09428224 Expired - Lifetime US6124305A (en) 1996-11-07 1999-10-20 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV

Country Status (1)

Country Link
US (2) US6011155A (en)

Cited By (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055105A1 (en) * 2000-01-24 2001-08-02 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
WO2001068603A2 (en) * 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
WO2001081337A1 (en) * 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
WO2001096295A2 (en) * 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
WO2002030890A1 (en) * 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Nitrogenous five-membered ring compounds
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
WO2002051836A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
EP1228061A1 (en) * 1999-11-12 2002-08-07 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
US20020165164A1 (en) * 1999-08-24 2002-11-07 Hans-Ulrich Demuth New effectors of dipeptidyl peptidase IV for topical use
US6531511B1 (en) 1999-01-26 2003-03-11 Vernalis Research Limited 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
WO2003035057A1 (en) * 2001-10-23 2003-05-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
US20030119738A1 (en) * 2001-09-06 2003-06-26 Andre Niestroj Novel inhibitors of dipeptidyl peptidase I
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
US20030134802A1 (en) * 1998-05-28 2003-07-17 Hans-Ulrich Demuth Novel effectors of dipepetidyl peptidase IV
EP1333025A1 (en) * 2000-11-10 2003-08-06 Taisho Pharmaceutical Co. Ltd Cyanopyrrolidine derivatives
US20030153509A1 (en) * 1998-02-02 2003-08-14 Bachovchin William W. Method of regulating glucose metabolism, and reagents related thereto
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US20030216450A1 (en) * 2000-04-26 2003-11-20 Evans David Michael Inhibitors of dipeptidyl peptidase IV
US20030216382A1 (en) * 2002-02-13 2003-11-20 Markus Boehringer Pyridine and pyrimidine derivatives
WO2003101448A1 (en) * 2002-06-03 2003-12-11 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
US20040043919A1 (en) * 2000-10-27 2004-03-04 Stephan Von Horsten Method for the treatment of neurological and neuropsychological disorders
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
US6770620B2 (en) * 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
US20040167341A1 (en) * 2001-06-27 2004-08-26 Haffner Curt Dale Pyrrolidines as dipeptidyl peptidase inhibitors
US20040171555A1 (en) * 1998-06-24 2004-09-02 Hans-Ulrich Demuth Prodrugs of DP IV-inhibitors
US20040171848A1 (en) * 2001-06-27 2004-09-02 Haffner Curt Dale Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20040188323A1 (en) * 2003-03-24 2004-09-30 Tzatzov Konstantin K. Active coating system for reducing or eliminating coke build-up during petrochemical processes
US6800650B2 (en) 2002-02-13 2004-10-05 Hoffmann-La Roche Inc. Pyridine and quinoline derivatives
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040214762A1 (en) * 2001-08-16 2004-10-28 Hans-Ulrich Demuth Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US20040224875A1 (en) * 2003-05-05 2004-11-11 Stephan Schilling Inhibitors of glutaminyl cyclase
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
US20040242636A1 (en) * 2001-06-27 2004-12-02 Haffner Curt Dale Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20040254167A1 (en) * 2002-10-18 2004-12-16 Tesfaye Biftu Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20040259903A1 (en) * 2003-06-20 2004-12-23 Markus Boehringer Pyrido [2,1-a] isoquinoline derivatives
US20040259902A1 (en) * 2003-06-20 2004-12-23 Markus Boehringer Pyrido [2,1-a] isoquinoline derivatives
US20040259843A1 (en) * 2002-09-19 2004-12-23 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050014703A1 (en) * 2000-03-31 2005-01-20 Hans-Ulrich Demuth Method for the improvement of islet signaling in diabetes mellitus and for its prevention
WO2005012331A1 (en) * 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocyclic compounds useful for drug discovery
US20050042614A1 (en) * 2001-10-31 2005-02-24 Hughes Thomas Edward Methods to treat diabetes and related conditions based on polymorphisms in the tcf-1 gene
US20050058635A1 (en) * 2003-05-05 2005-03-17 Hans-Ulrich Demuth Use of effectors of glutaminyl and glutamate cyclases
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050065145A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
US20050070530A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070482A1 (en) * 2001-11-26 2005-03-31 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
US20050131019A1 (en) * 2003-09-04 2005-06-16 Zhonghua Pei Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20050171025A1 (en) * 2001-06-27 2005-08-04 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20050192324A1 (en) * 2004-02-03 2005-09-01 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US20050215784A1 (en) * 2002-09-19 2005-09-29 Madar David J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050261271A1 (en) * 2004-03-15 2005-11-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050272765A1 (en) * 2004-06-04 2005-12-08 Jun Feng Dipeptidyl peptidase inhibitors
US20060014953A1 (en) * 2002-10-07 2006-01-19 Dooseop Kim Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
US20060040963A1 (en) * 2002-07-15 2006-02-23 Mathvink Robert J Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060069116A1 (en) * 2003-01-17 2006-03-30 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060074087A1 (en) * 2003-01-31 2006-04-06 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060106087A1 (en) * 2002-08-29 2006-05-18 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
US20060111428A1 (en) * 2002-12-10 2006-05-25 Pei-Ran Wang Combination of an dpp-iv inhibitor and a ppar-alpha compound
US20060111336A1 (en) * 2002-12-04 2006-05-25 Duffy Joseph L Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060116393A1 (en) * 2004-11-30 2006-06-01 Markus Boehringer Substituted pyrido [2,1-a] isoquinoline derivatives
US20060135561A1 (en) * 2004-12-20 2006-06-22 Markus Boehringer 4-Aminopiperidine derivatives
US20060135767A1 (en) * 2004-12-21 2006-06-22 Jun Feng Dipeptidyl peptidase inhibitors
US20060135512A1 (en) * 2004-12-20 2006-06-22 Markus Boehringer Aminocycloalkanes as DPP-IV inhibitors
US20060189523A1 (en) * 2003-10-15 2006-08-24 Stephan Schilling Use of effectors of glutaminyl and glutamate cyclases
US20060211682A1 (en) * 2003-07-31 2006-09-21 Gui-Bai Liang Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2006273873A (en) * 2000-01-21 2006-10-12 Novartis Ag Combinations comprising dipeptidyl peptidase-iv inhibitor and antidiabetic agents
US20060229286A1 (en) * 2003-01-31 2006-10-12 Takuji Kakigami Compound inhibiting dipeptidyl peptidase IV
US20060258646A1 (en) * 2003-05-14 2006-11-16 Tesfaye Biftu 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060258621A1 (en) * 2003-11-12 2006-11-16 Campbell David A Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20060264401A1 (en) * 2003-11-12 2006-11-23 Campbell David A Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20060264400A1 (en) * 2003-11-12 2006-11-23 Campbell David A Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20060264433A1 (en) * 2005-05-23 2006-11-23 Backes Bradley J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20060270701A1 (en) * 2005-04-22 2006-11-30 Alantos Pharmaceuticals, Inc. Dipeptidyl peptidase-IV inhibitors
US20060276410A1 (en) * 2005-05-25 2006-12-07 Campbell David A Compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20060281796A1 (en) * 2003-06-06 2006-12-14 Edmondson Scott D Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060281727A1 (en) * 2003-11-04 2006-12-14 Ashton Wallace T Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20070010423A1 (en) * 2003-06-27 2007-01-11 Karsten Wassermann Compositions comprising balaglitazone and further antidiabetic compounds
US20070021477A1 (en) * 2003-06-17 2007-01-25 Edmondson Scott D Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070060547A1 (en) * 2003-11-12 2007-03-15 Phenomix Corporation Heterocyclic boronic acid compounds
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US20070060530A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US20070060528A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US20070066636A1 (en) * 2005-09-16 2007-03-22 Chyall Leonard J Polymorphs of tartrate salt of 2-[2-(3-(r)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6h-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
US20070066635A1 (en) * 2005-09-16 2007-03-22 Mark Andres Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US7205323B2 (en) 2004-10-12 2007-04-17 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation
US20070099913A1 (en) * 2005-10-31 2007-05-03 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US20070098781A1 (en) * 2005-08-11 2007-05-03 Loeffler Bernd M Modified release compositions for DPP-IV inhibitors
WO2007077508A2 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
US20070238753A1 (en) * 2004-02-27 2007-10-11 Madar David J Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
US20070244177A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
US7314884B2 (en) 2001-10-26 2008-01-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20080021009A1 (en) * 2004-05-04 2008-01-24 Jinyou Xu 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
US20080027093A1 (en) * 2004-05-18 2008-01-31 Duffy Joseph L Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
US20080051383A1 (en) * 2006-07-06 2008-02-28 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US20080076811A1 (en) * 2000-01-21 2008-03-27 Bork Balkan Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20080227798A1 (en) * 2006-11-29 2008-09-18 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20080234292A1 (en) * 2004-07-23 2008-09-25 Susan Marie Royalty Peptidase Inhibitors
US20080287476A1 (en) * 2007-03-13 2008-11-20 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US20080300251A1 (en) * 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
US20090054314A1 (en) * 2005-10-07 2009-02-26 Antonio Cruz Combined use of DPP-IV inhibitors and gastrin compounds
US20090275750A1 (en) * 2005-09-16 2009-11-05 Jun Feng Dipeptidyl peptidase inhibitors
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100099721A1 (en) * 2003-11-03 2010-04-22 Probiodrug Ag Novel compounds for the treatment of neurological disorders
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
US20100286365A1 (en) * 2007-09-27 2010-11-11 Amylin Pharmaceuticals, Inc. Peptide-peptidase-inhibitor conjugates and methods of making and using same
US20100292172A1 (en) * 2006-03-21 2010-11-18 Amylin Pharmaceuticals, Inc. Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same
US20100291020A1 (en) * 2007-09-21 2010-11-18 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2338490A2 (en) 2003-11-03 2011-06-29 Probiodrug AG Combinations Useful for the Treatment of Neuronal Disorders
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011153953A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
EP2636680A2 (en) 2006-05-26 2013-09-11 Amylin Pharmaceuticals, LLC Composition and methods for treatment of congestive heart failure
WO2014020462A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of vildagliptin intermediate
WO2014061031A1 (en) 2012-10-17 2014-04-24 Cadila Healthcare Limited 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP3087975A1 (en) 2004-08-27 2016-11-02 Novartis Ag Treatment with vildagliptin
US9907848B2 (en) 2010-08-03 2018-03-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for treatment of metabolic disorders

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0014969D0 (en) 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
WO2002002560A3 (en) 2000-07-04 2002-04-25 Novo Nordisk As Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
US20080249016A1 (en) * 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20070135345A1 (en) * 2000-09-18 2007-06-14 Henriksen Dennis B Use of GLP-2 for the treatment or prevention, of bone-related disorders
GB0109146D0 (en) * 2001-04-11 2001-05-30 Ferring Bv Treatment of type 2 diabetes
EP1504525A2 (en) * 2002-05-14 2005-02-09 Siemens Aktiengesellschaft Method for producing a transmission signal
WO2005033099A3 (en) * 2003-10-03 2005-06-30 Sandeep Raghunath Ghorpade Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
US20060094782A9 (en) * 2003-10-31 2006-05-04 Wong Patrick S Compositions and dosage forms for enhanced absorption
KR101259645B1 (en) 2004-01-20 2013-04-30 노파르티스 아게 Direct compression formulation and process
EP1906991A2 (en) * 2004-06-28 2008-04-09 Novo Nordisk A/S Use of glp-1 receptor agonists and/or dpp-iv inhibitors in combination with proton pump inhibitors and ppar agonists for the preparation of a medicament for the treatment of diabetes type i, diabetes type ii and impaired pancreatic beta-cell function
US7786163B2 (en) * 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE158109C (en) *
US4229465A (en) * 1978-07-10 1980-10-21 Nippon Soda Company, Ltd. Cyanopyrrole derivatives
US4849435A (en) * 1987-01-31 1989-07-18 Bayer Aktiengesellschaft Fungicidal 1-aminomethyl-3-aryl-4-cyano-pyrroles
EP0339422A1 (en) * 1988-04-29 1989-11-02 Bayer Ag 3-Cyano-4-phenyl-pyrrole derivatives
US4923883A (en) * 1987-01-31 1990-05-08 Bayer Aktiengesellschaft 1-Aminomethyl-3-aryl-4-cyano-pyrroles and their use as fungicides
WO1990012005A1 (en) * 1989-04-13 1990-10-18 Japan Tobacco Inc. New amino acid derivatives having prolylendopeptidase inhibitor activity
US4977182A (en) * 1988-04-29 1990-12-11 Bayer Aktiengesellschaft Fungicidal 3-cyano-4-phenyl-pyrroles
WO1991016339A1 (en) * 1990-04-14 1991-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
WO1993008259A2 (en) * 1991-10-22 1993-04-29 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
EP0555824A1 (en) * 1992-02-13 1993-08-18 Dr. Karl Thomae GmbH N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1995029190A1 (en) * 1994-04-22 1995-11-02 Institut Pasteur Multirepresentation of a peptide analogue of the dppiv substrate, especially of the kpr type, to inhibit the entry of hiv in cells
WO1995029691A1 (en) * 1994-04-28 1995-11-09 Georgia Tech Research Corporation Proline phosphonate derivatives
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE29607550U1 (en) * 1996-04-26 1996-07-18 Porsche Ag Motor vehicle, especially racing cars

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE158109C (en) *
US4229465A (en) * 1978-07-10 1980-10-21 Nippon Soda Company, Ltd. Cyanopyrrole derivatives
US4849435A (en) * 1987-01-31 1989-07-18 Bayer Aktiengesellschaft Fungicidal 1-aminomethyl-3-aryl-4-cyano-pyrroles
US4923883A (en) * 1987-01-31 1990-05-08 Bayer Aktiengesellschaft 1-Aminomethyl-3-aryl-4-cyano-pyrroles and their use as fungicides
EP0339422A1 (en) * 1988-04-29 1989-11-02 Bayer Ag 3-Cyano-4-phenyl-pyrrole derivatives
US4977182A (en) * 1988-04-29 1990-12-11 Bayer Aktiengesellschaft Fungicidal 3-cyano-4-phenyl-pyrroles
WO1990012005A1 (en) * 1989-04-13 1990-10-18 Japan Tobacco Inc. New amino acid derivatives having prolylendopeptidase inhibitor activity
WO1991016339A1 (en) * 1990-04-14 1991-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
WO1993008259A2 (en) * 1991-10-22 1993-04-29 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type iv
EP0555824A1 (en) * 1992-02-13 1993-08-18 Dr. Karl Thomae GmbH N-alpha-arylsulfonylated benzimidazolylalaninamide derivatives, medicaments based thereon and process for their preparation
WO1995011689A1 (en) * 1993-10-29 1995-05-04 Trustees Of Tufts College Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1995015309A1 (en) * 1993-12-03 1995-06-08 Ferring B.V. Dp-iv-serine protease inhibitors
WO1995029190A1 (en) * 1994-04-22 1995-11-02 Institut Pasteur Multirepresentation of a peptide analogue of the dppiv substrate, especially of the kpr type, to inhibit the entry of hiv in cells
WO1995029691A1 (en) * 1994-04-28 1995-11-09 Georgia Tech Research Corporation Proline phosphonate derivatives
WO1995034538A2 (en) * 1994-06-10 1995-12-21 Universitaire Instelling Antwerpen Purification of serine proteases and synthetic inhibitors thereof

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
Ashworth et al., Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 10, pp. 1163 1166 (1996). *
Ashworth et al., Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 10, pp. 1163-1166 (1996).
Ashworth et al., Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 22, pp. 2745 2748 (1996). *
Ashworth et al., Bioorganic and Medicinal Chemistry Letters, vol. 6, No. 22, pp. 2745-2748 (1996).
Augustyns et al., Eur. J. Med. Chem., vol. 32, pp. 301 309 (1997). *
Augustyns et al., Eur. J. Med. Chem., vol. 32, pp. 301-309 (1997).
Chemical Abstracts 84: 177689. (1984). *
Chemical Abstracts 95: 302548. (1995). *
Chemical Abstracts 96: 116353 (1996). *
Coutts et al., J. Med. Chem., vol. 39, pp. 2087 2094 (1996). *
Coutts et al., J. Med. Chem., vol. 39, pp. 2087-2094 (1996).
Deacon et al., Diabetes, vol. 44, pp. 1126 1131 (Sep. 96). *
Deacon et al., Diabetes, vol. 44, pp. 1126-1131 (Sep. '96).
Kaspari et al., Biochimica et Biophysica, vol. 1293, pp. 147 153. (1996). *
Kaspari et al., Biochimica et Biophysica, vol. 1293, pp. 147-153. (1996).
Li et al, Archives of Biochemistry and Biophysics vol. 323, No. 1, pp. 148 154 (1995). *
Li et al, Archives of Biochemistry and Biophysics vol. 323, No. 1, pp. 148-154 (1995).
Li et al, Journal of Neurochemistry, vol. 66, pp. 2105 2112 (1996). *
Li et al, Journal of Neurochemistry, vol. 66, pp. 2105-2112 (1996).
Yamada et al, Bulletin of the Chemical Society of Japan, vol. 50, No. 7, pp. 1827 1830 (1977). *
Yamada et al, Bulletin of the Chemical Society of Japan, vol. 50, No. 7, pp. 1827-1830 (1977).
Yamada et al., Bulletin of the Chemical Society of Japan, vol. 51, No. 3, pp. 878 883 (1978). *
Yamada et al., Bulletin of the Chemical Society of Japan, vol. 51, No. 3, pp. 878-883 (1978).

Cited By (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050107309A1 (en) * 1996-04-25 2005-05-19 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals
US7157429B1 (en) * 1998-02-02 2007-01-02 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US7829530B2 (en) 1998-02-02 2010-11-09 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US20040176307A1 (en) * 1998-02-02 2004-09-09 Bachovchin William W. Method of regulating glucose metabolism, and reagents related thereto
US6803357B1 (en) * 1998-02-02 2004-10-12 New England Medical Center Hospitals, Inc. Method of regulating glucose metabolism, and reagents related thereto
US20030153509A1 (en) * 1998-02-02 2003-08-14 Bachovchin William W. Method of regulating glucose metabolism, and reagents related thereto
US20110172149A1 (en) * 1998-02-02 2011-07-14 Trustees Of Tufts College Method of Regulating Glucose Metabolism, and Reagents Related Thereto
US9044424B2 (en) 1998-02-02 2015-06-02 1149336 Ontario, Inc. Methods of regulating glucose metabolism, and reagents related thereto
US20090082309A1 (en) * 1998-02-02 2009-03-26 Trustees Of Tufts College Method of Regulating Glucose Metabolism, and Reagents Related Thereto
US7078381B2 (en) * 1998-02-02 2006-07-18 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US8513190B2 (en) 1998-02-02 2013-08-20 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US6890898B2 (en) 1998-02-02 2005-05-10 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US8318669B2 (en) * 1998-02-02 2012-11-27 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US7459428B2 (en) 1998-02-02 2008-12-02 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
US20030134802A1 (en) * 1998-05-28 2003-07-17 Hans-Ulrich Demuth Novel effectors of dipepetidyl peptidase IV
US20080182798A1 (en) * 1998-05-28 2008-07-31 Hans-Ulrich Demuth Novel effectors of dipeptidyl peptidase IV
US20050203030A1 (en) * 1998-05-28 2005-09-15 Hans-Ulrich Demuth Novel effectors of dipeptidyl peptidase IV
US20040171555A1 (en) * 1998-06-24 2004-09-02 Hans-Ulrich Demuth Prodrugs of DP IV-inhibitors
US7166579B2 (en) 1998-06-24 2007-01-23 Prosidion Limited Prodrugs of DP IV-inhibitors
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
US20030176357A1 (en) * 1998-10-06 2003-09-18 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US20020110560A1 (en) * 1998-10-06 2002-08-15 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals
US6531511B1 (en) 1999-01-26 2003-03-11 Vernalis Research Limited 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission
US6949515B2 (en) 1999-08-24 2005-09-27 Probiodrug Ag Effectors of dipeptidyl peptidase IV for topical use
US20030092630A2 (en) * 1999-08-24 2003-05-15 Probiodrug Ag New effectors of dipeptidyl peptidase iv for topical use
US20050209159A1 (en) * 1999-08-24 2005-09-22 Hans-Ulrich Demuth Effectors of dipeptidyl peptidase IV for topical use
US20020165164A1 (en) * 1999-08-24 2002-11-07 Hans-Ulrich Demuth New effectors of dipeptidyl peptidase IV for topical use
US7335645B2 (en) 1999-08-24 2008-02-26 Probiodrug Ag Effectors of dipeptidyl peptidase IV for topical use
US20040152745A1 (en) * 1999-11-12 2004-08-05 Guilford Pharmaceuticals, Inc. Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors
EP1228061A1 (en) * 1999-11-12 2002-08-07 Guilford Pharmaceuticals Inc. Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
EP1228061A4 (en) * 1999-11-12 2004-12-15 Guilford Pharm Inc Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors
US6380398B2 (en) * 2000-01-04 2002-04-30 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2011162550A (en) * 2000-01-21 2011-08-25 Novartis Ag Combination comprising dipeptidylpeptidase-iv inhibitor and antidiabetic agent
JP2011116772A (en) * 2000-01-21 2011-06-16 Novartis Ag Combination comprising dipeptidylpeptidase-iv inhibitor and antidiabetic agent
US20080076811A1 (en) * 2000-01-21 2008-03-27 Bork Balkan Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents
JP2006273873A (en) * 2000-01-21 2006-10-12 Novartis Ag Combinations comprising dipeptidyl peptidase-iv inhibitor and antidiabetic agents
WO2001055105A1 (en) * 2000-01-24 2001-08-02 Novo Nordisk A/S N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv
US6645995B2 (en) 2000-01-24 2003-11-11 Novo Nordisk A/S Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV
JP2010077163A (en) * 2000-03-10 2010-04-08 Bristol Myers Squibb Co Cyclopropyl-fused pyrrolidine-based inhibitor for dipeptidyl peptidase iv, and method
EP2995615A1 (en) * 2000-03-10 2016-03-16 AstraZeneca AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and their pharmaceutical use
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2014040486A (en) * 2000-03-10 2014-03-06 Bristol Myers Squibb Co Inhibitors of dipeptidyl peptidase iv having cyclopropyl-fused pyrrolidine backbone and method
WO2001068603A2 (en) * 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
KR100758407B1 (en) 2000-03-10 2007-09-14 브리스톨-마이어스스퀴브컴파니 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
KR100754089B1 (en) 2000-03-10 2007-08-31 브리스톨-마이어스스퀴브컴파니 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
USRE44186E1 (en) 2000-03-10 2013-04-30 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
JP2015134830A (en) * 2000-03-10 2015-07-27 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Inhibitors of dipeptidyl peptidase iv having cyclopropyl-fused pyrrolidine backbone and method
WO2001068603A3 (en) * 2000-03-10 2002-02-14 Bristol Myers Squibb Co Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
EP1559710A3 (en) * 2000-03-10 2009-07-22 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
EP1559710A2 (en) 2000-03-10 2005-08-03 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, process for their preparation and their use
JP2013040219A (en) * 2000-03-10 2013-02-28 Bristol Myers Squibb Co Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv and method
US20050222221A1 (en) * 2000-03-31 2005-10-06 Hans-Ulrich Demuth Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US20050014703A1 (en) * 2000-03-31 2005-01-20 Hans-Ulrich Demuth Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US7189728B2 (en) * 2000-04-26 2007-03-13 Ferring, Bv Inhibitors of dipeptidyl peptidase IV
US20040082497A1 (en) * 2000-04-26 2004-04-29 Evans David Michael Inhibitors of dipeptidyl peptidase IV
US20030216450A1 (en) * 2000-04-26 2003-11-20 Evans David Michael Inhibitors of dipeptidyl peptidase IV
US7125863B2 (en) 2000-04-26 2006-10-24 Ferring Bv Inhibitors of dipeptidyl peptidase IV
WO2001081337A1 (en) * 2000-04-26 2001-11-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
US6432969B1 (en) 2000-06-13 2002-08-13 Novartis Ag N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
JP2004503531A (en) * 2000-06-13 2004-02-05 ノバルティス アクチエンゲゼルシャフト 2-cyano pyrrolidines their use as derivatives and pharmaceutical
WO2001096295A3 (en) * 2000-06-13 2002-05-16 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
US20020193390A1 (en) * 2000-06-13 2002-12-19 Villhauer Edwin Bernard Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV
WO2001096295A2 (en) * 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
US6770620B2 (en) * 2000-09-18 2004-08-03 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002030890A1 (en) * 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Nitrogenous five-membered ring compounds
US7160877B2 (en) 2000-10-06 2007-01-09 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogen-containing 5-membered ring compound
US7138397B2 (en) 2000-10-06 2006-11-21 Tanabe Seiyaku Co., Ltd. Nitrogenous 5-membered ring compounds
US20060241146A1 (en) * 2000-10-06 2006-10-26 Tanabe Seiyaku Co., Ltd. Nitrogen-containing 5-membered ring compound
US20080153821A1 (en) * 2000-10-06 2008-06-26 Tanabe Seiyaku Co., Ltd. Nitrogen-containing 5-membered ring compound
US20040229926A1 (en) * 2000-10-06 2004-11-18 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogen - containing 5 - membered ring compound
US20050054678A1 (en) * 2000-10-06 2005-03-10 Kosuke Yasuda Nitrogenous five-membered ring compounds
WO2002030891A1 (en) * 2000-10-06 2002-04-18 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
US7666869B2 (en) 2000-10-06 2010-02-23 Mitsubishi Tanabe Pharma Corp. Nitrogen-containing 5-membered ring compound
US6849622B2 (en) 2000-10-06 2005-02-01 Tanabe Seiyaku Co., Ltd. Aliphatic nitrogenous five-membered ring compounds
US7332487B2 (en) 2000-10-06 2008-02-19 Tanabe Seiyaku Co., Ltd. Nitrogen-containing 5-membered ring compound
US20040043919A1 (en) * 2000-10-27 2004-03-04 Stephan Von Horsten Method for the treatment of neurological and neuropsychological disorders
EP1746086A1 (en) * 2000-11-10 2007-01-24 Taisho Pharmaceutical Co. Ltd Cyanopyrrolidine derivatives
EP1333025A1 (en) * 2000-11-10 2003-08-06 Taisho Pharmaceutical Co. Ltd Cyanopyrrolidine derivatives
EP1333025A4 (en) * 2000-11-10 2004-03-24 Taisho Pharma Co Ltd Cyanopyrrolidine derivatives
US20040072892A1 (en) * 2000-11-10 2004-04-15 Hiroshi Fukushima Cyanopyrrolidine derivatives
WO2002051836A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
US20080261864A1 (en) * 2001-03-12 2008-10-23 Edwin Bernard Villhauer Combination of nateglinide or repaglinide with at least one further antidiabetic compound
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
WO2002083128A1 (en) 2001-04-12 2002-10-24 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
EP1377288A1 (en) * 2001-04-12 2004-01-07 Bristol-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
EP1377288A4 (en) * 2001-04-12 2005-03-16 Squibb Bristol Myers Co 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase iv and method
US20030060494A1 (en) * 2001-05-18 2003-03-27 Nobuyuki Yasuda Pharmaceutical use of N-carbamoylazole derivatives
US7109347B2 (en) 2001-06-27 2006-09-19 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20030119750A1 (en) * 2001-06-27 2003-06-26 Hans-Ulrich Demuth Use of dipeptidyl peptidase IV inhibitors
US20060293248A1 (en) * 2001-06-27 2006-12-28 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US20040167341A1 (en) * 2001-06-27 2004-08-26 Haffner Curt Dale Pyrrolidines as dipeptidyl peptidase inhibitors
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US7196201B2 (en) 2001-06-27 2007-03-27 Smithkline Beecham Corporation Pyrrolidines as dipeptidyl peptidase inhibitors
US20040242636A1 (en) * 2001-06-27 2004-12-02 Haffner Curt Dale Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US7368576B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7132443B2 (en) 2001-06-27 2006-11-07 Smithklinebeecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20050171025A1 (en) * 2001-06-27 2005-08-04 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US7183290B2 (en) 2001-06-27 2007-02-27 Smithkline Beecham Corporation Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20040171848A1 (en) * 2001-06-27 2004-09-02 Haffner Curt Dale Fluoropyrrolidines as dipeptidyl peptidase inhibitors
US20040214762A1 (en) * 2001-08-16 2004-10-28 Hans-Ulrich Demuth Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades
US20070207946A1 (en) * 2001-08-17 2007-09-06 Pospisilik Andrew J Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US20050107308A1 (en) * 2001-08-17 2005-05-19 Pospisilik Andrew J. Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
US20050233978A1 (en) * 2001-09-06 2005-10-20 Andre Niestroj Novel inhibitors of dipeptidyl peptidase I
US20030119738A1 (en) * 2001-09-06 2003-06-26 Andre Niestroj Novel inhibitors of dipeptidyl peptidase I
US7144856B2 (en) 2001-09-06 2006-12-05 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP1446116A1 (en) * 2001-10-23 2004-08-18 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
US7335677B2 (en) * 2001-10-23 2008-02-26 Ferring B.V. Inhibitors of dipeptidyl peptidase IV
WO2003035057A1 (en) * 2001-10-23 2003-05-01 Ferring B.V. Inhibitors of dipeptidyl peptidase iv
US20050043299A1 (en) * 2001-10-23 2005-02-24 Ferring B. V. Inhibitors of dipeptidyl peptidase iv
US20080255126A1 (en) * 2001-10-23 2008-10-16 Ferring B.V. Inhibitors of post-proline cleaving proteases
US7803819B2 (en) 2001-10-26 2010-09-28 Hoffmann-La Roche Inc. DPP IV inhibitors
US7314884B2 (en) 2001-10-26 2008-01-01 Hoffmann-La Roche Inc. DPP IV inhibitors
US20050042614A1 (en) * 2001-10-31 2005-02-24 Hughes Thomas Edward Methods to treat diabetes and related conditions based on polymorphisms in the tcf-1 gene
US7727964B2 (en) 2001-11-26 2010-06-01 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US9757400B2 (en) 2001-11-26 2017-09-12 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US8410053B2 (en) 2001-11-26 2013-04-02 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
US20050070482A1 (en) * 2001-11-26 2005-03-31 Trustees Of Tufts College Peptidomimetic inhibitors of post-proline cleaving enzymes
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
US20110082108A1 (en) * 2001-11-26 2011-04-07 Trustees Of Tufts College Peptidomimetic Inhibitors of Post-Proline Cleaving Enzymes
US6867205B2 (en) 2002-02-13 2005-03-15 Hoffman-La Roche Inc. Pyridine and pyrimidine derivatives
US20050143405A1 (en) * 2002-02-13 2005-06-30 Markus Boehringer Pyridine and pyrimidine derivatives
US6800650B2 (en) 2002-02-13 2004-10-05 Hoffmann-La Roche Inc. Pyridine and quinoline derivatives
US7022718B2 (en) 2002-02-13 2006-04-04 Hoffmann-La Roche Inc. Pyridine and pyrimidine derivatives
US20030216382A1 (en) * 2002-02-13 2003-11-20 Markus Boehringer Pyridine and pyrimidine derivatives
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
US20040082570A1 (en) * 2002-02-25 2004-04-29 Eisai Co., Ltd. Xanthine derivative and DPPIV inhibitor
US20030232761A1 (en) * 2002-03-28 2003-12-18 Hinke Simon A. Novel analogues of glucose-dependent insulinotropic polypeptide
WO2003101448A1 (en) * 2002-06-03 2003-12-11 Novartis Ag The use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US20050176806A1 (en) * 2002-06-03 2005-08-11 Holmes David G. Use of substituted cyanopyrrolidines and combination preparations containing them for treating hyperlipidemia and associated diseases
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US7208498B2 (en) 2002-07-15 2007-04-24 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20060040963A1 (en) * 2002-07-15 2006-02-23 Mathvink Robert J Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
US20060106087A1 (en) * 2002-08-29 2006-05-18 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
US7304166B2 (en) * 2002-08-29 2007-12-04 Taisho Pharmaceutical Co., Ltd. Benzenesulfonate salt of 4-fluoro-2-cyanopyrrolidine derivatives
US20040058876A1 (en) * 2002-09-18 2004-03-25 Torsten Hoffmann Secondary binding site of dipeptidyl peptidase IV (DP IV)
US20050176622A1 (en) * 2002-09-18 2005-08-11 Kerstin Kuhn-Wache Secondary binding site of dipeptidyl peptidase IV (DPIV)
US20100190822A1 (en) * 2002-09-19 2010-07-29 Abbott Laboratories Pharmaceutical Compositions As Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
US20050215784A1 (en) * 2002-09-19 2005-09-29 Madar David J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7262207B2 (en) * 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US8119664B2 (en) 2002-09-19 2012-02-21 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20070265302A1 (en) * 2002-09-19 2007-11-15 Madar David J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
US8637546B2 (en) 2002-09-19 2014-01-28 Abbvie Inc. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DDP-IV)
US7238724B2 (en) 2002-09-19 2007-07-03 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040259843A1 (en) * 2002-09-19 2004-12-23 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040121964A1 (en) * 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7390809B2 (en) 2002-10-07 2008-06-24 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for diabetes
US20060014953A1 (en) * 2002-10-07 2006-01-19 Dooseop Kim Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20040254167A1 (en) * 2002-10-18 2004-12-16 Tesfaye Biftu Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7101871B2 (en) 2002-10-18 2006-09-05 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060189520A1 (en) * 2002-10-22 2006-08-24 Brand Stephen J Treatment of diabetes
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US7309714B2 (en) 2002-12-04 2007-12-18 Merck & Co., Inc. Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060111336A1 (en) * 2002-12-04 2006-05-25 Duffy Joseph L Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060111428A1 (en) * 2002-12-10 2006-05-25 Pei-Ran Wang Combination of an dpp-iv inhibitor and a ppar-alpha compound
US20080300293A1 (en) * 2002-12-10 2008-12-04 Pei-Ran Wang Combination of an dpp-iv inhibitor and a ppar-alpha compound
US20060052382A1 (en) * 2002-12-20 2006-03-09 Duffy Joseph L 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060069116A1 (en) * 2003-01-17 2006-03-30 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7265128B2 (en) 2003-01-17 2007-09-04 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7388019B2 (en) 2003-01-31 2008-06-17 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060074087A1 (en) * 2003-01-31 2006-04-06 Ashton Wallace T 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060229286A1 (en) * 2003-01-31 2006-10-12 Takuji Kakigami Compound inhibiting dipeptidyl peptidase IV
US7345180B2 (en) 2003-01-31 2008-03-18 Sanwa Kagaku Kenkyusho Co., Ltd. Compound inhibiting dipeptidyl peptidase IV
US20040188323A1 (en) * 2003-03-24 2004-09-30 Tzatzov Konstantin K. Active coating system for reducing or eliminating coke build-up during petrochemical processes
US20040242568A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050004117A1 (en) * 2003-03-25 2005-01-06 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7687625B2 (en) 2003-03-25 2010-03-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20040259870A1 (en) * 2003-03-25 2004-12-23 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20040242566A1 (en) * 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
DE202004021723U1 (en) 2003-05-05 2010-07-15 Probiodrug Ag Medical use of inhibitors of glutaminyl and Glutamatcyclasen
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
US20050058635A1 (en) * 2003-05-05 2005-03-17 Hans-Ulrich Demuth Use of effectors of glutaminyl and glutamate cyclases
US7371871B2 (en) 2003-05-05 2008-05-13 Probiodrug Ag Inhibitors of glutaminyl cyclase
US7381537B2 (en) 2003-05-05 2008-06-03 Probiodrug Ag Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease
WO2004098625A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
US20040224875A1 (en) * 2003-05-05 2004-11-11 Stephan Schilling Inhibitors of glutaminyl cyclase
EP2206496A1 (en) 2003-05-05 2010-07-14 Probiodrug AG Medical use of inhibitors of glutaminyl and glutamate cyclases
US7638638B2 (en) 2003-05-14 2009-12-29 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20060258646A1 (en) * 2003-05-14 2006-11-16 Tesfaye Biftu 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7560455B2 (en) 2003-05-14 2009-07-14 Merck & Co., Inc. 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7332520B2 (en) 2003-06-06 2008-02-19 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20060281796A1 (en) * 2003-06-06 2006-12-14 Edmondson Scott D Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US20070021477A1 (en) * 2003-06-17 2007-01-25 Edmondson Scott D Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7456204B2 (en) 2003-06-17 2008-11-25 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7122555B2 (en) 2003-06-20 2006-10-17 Hoffmann-La Roche Inc. Pyrido [2,1-a] isoquinoline derivatives
US20040259902A1 (en) * 2003-06-20 2004-12-23 Markus Boehringer Pyrido [2,1-a] isoquinoline derivatives
WO2005000848A1 (en) 2003-06-20 2005-01-06 F. Hoffmann-La Roche Ag Pyrido` 2, 1-a - isoquinoline derivatives as dpp-iv inhibitors
US7718666B2 (en) 2003-06-20 2010-05-18 Hoffmann-La Roche Inc. Pyrido [2,1-a] isoquinoline derivatives
US20040259903A1 (en) * 2003-06-20 2004-12-23 Markus Boehringer Pyrido [2,1-a] isoquinoline derivatives
US20090312350A1 (en) * 2003-06-27 2009-12-17 Karsten Wassermann Compositions comprising balaglitazone and further antidiabetic compounds
US20070010423A1 (en) * 2003-06-27 2007-01-11 Karsten Wassermann Compositions comprising balaglitazone and further antidiabetic compounds
US7259160B2 (en) 2003-07-31 2007-08-21 Merck & Co., Inc. Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2005012331A1 (en) * 2003-07-31 2005-02-10 Tranzyme Pharma Spatially-defined macrocyclic compounds useful for drug discovery
US7452862B2 (en) 2003-07-31 2008-11-18 Tranzyme Pharma, Inc. Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
US8022252B2 (en) 2003-07-31 2011-09-20 Tranzyme Pharma Inc. Spatially-defined macrocyclic compounds useful for drug discovery
US20060211682A1 (en) * 2003-07-31 2006-09-21 Gui-Bai Liang Hexahydrodiazepinones as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20050070531A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7723344B2 (en) 2003-08-13 2010-05-25 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050070706A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050070535A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050070530A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7790736B2 (en) 2003-08-13 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20050131019A1 (en) * 2003-09-04 2005-06-16 Zhonghua Pei Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20050065144A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US20050065145A1 (en) * 2003-09-08 2005-03-24 Syrrx, Inc. Dipeptidyl peptidase inhibitors
US7790734B2 (en) 2003-09-08 2010-09-07 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2289498A1 (en) 2003-10-15 2011-03-02 Probiodrug AG Use of inhibitors of glutaminyl clyclase
US20060189523A1 (en) * 2003-10-15 2006-08-24 Stephan Schilling Use of effectors of glutaminyl and glutamate cyclases
US7462599B2 (en) 2003-10-15 2008-12-09 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20100159032A1 (en) * 2003-11-03 2010-06-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US20100099721A1 (en) * 2003-11-03 2010-04-22 Probiodrug Ag Novel compounds for the treatment of neurological disorders
EP2338490A2 (en) 2003-11-03 2011-06-29 Probiodrug AG Combinations Useful for the Treatment of Neuronal Disorders
US20060281727A1 (en) * 2003-11-04 2006-12-14 Ashton Wallace T Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7238683B2 (en) 2003-11-04 2007-07-03 Merck & Co., Inc. Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20060264401A1 (en) * 2003-11-12 2006-11-23 Campbell David A Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US7906658B2 (en) 2003-11-12 2011-03-15 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20070299036A1 (en) * 2003-11-12 2007-12-27 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20080182995A1 (en) * 2003-11-12 2008-07-31 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
EP1997533A1 (en) 2003-11-12 2008-12-03 Phenomix Corporation Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7884217B2 (en) 2003-11-12 2011-02-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060264400A1 (en) * 2003-11-12 2006-11-23 Campbell David A Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US7674913B2 (en) 2003-11-12 2010-03-09 Phenomix Corporation Heterocyclic boronic acid compounds
US20060258621A1 (en) * 2003-11-12 2006-11-16 Campbell David A Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20070060547A1 (en) * 2003-11-12 2007-03-15 Phenomix Corporation Heterocyclic boronic acid compounds
US8415295B2 (en) 2003-11-12 2013-04-09 Phenomix Corporation Heterocyclic boronic acid compounds
US20100120661A1 (en) * 2003-11-12 2010-05-13 Phenomix Corporation Heterocyclic boronic acid compounds
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US20050192324A1 (en) * 2004-02-03 2005-09-01 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
US7897633B2 (en) 2004-02-05 2011-03-01 Probiodrug Ag Inhibitors of glutaminyl cyclase
WO2005075436A2 (en) 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20070238753A1 (en) * 2004-02-27 2007-10-11 Madar David J Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8288539B2 (en) 2004-03-15 2012-10-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7781584B2 (en) 2004-03-15 2010-08-24 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8173663B2 (en) 2004-03-15 2012-05-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7906523B2 (en) 2004-03-15 2011-03-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080108808A1 (en) * 2004-03-15 2008-05-08 Jun Feng Dipeptidyl peptidase inhibitors
US20080108807A1 (en) * 2004-03-15 2008-05-08 Jun Feng Dipeptidyl peptidase inhibitors
US7807689B2 (en) 2004-03-15 2010-10-05 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080188501A1 (en) * 2004-03-15 2008-08-07 Jun Feng Dipeptidyl peptidase inhibitors
US8329900B2 (en) 2004-03-15 2012-12-11 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080161562A1 (en) * 2004-03-15 2008-07-03 Jun Feng Dipeptidyl peptidase inhibitors
US20050261271A1 (en) * 2004-03-15 2005-11-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US8188275B2 (en) 2004-03-15 2012-05-29 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20080177064A1 (en) * 2004-03-15 2008-07-24 Jun Feng Dipeptidyl peptidase inhibitors
US7687492B2 (en) 2004-05-04 2010-03-30 Merck Sharp & Dohme Corp. 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20080021009A1 (en) * 2004-05-04 2008-01-24 Jinyou Xu 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
US20080027093A1 (en) * 2004-05-18 2008-01-31 Duffy Joseph L Cyclohexylalanine Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
US7671073B2 (en) 2004-05-18 2010-03-02 Merck Sharp & Dohme Corp. Cyclohexylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
US20050272765A1 (en) * 2004-06-04 2005-12-08 Jun Feng Dipeptidyl peptidase inhibitors
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7825242B2 (en) 2004-07-16 2010-11-02 Takeda Pharmaceutical Company Limted Dipeptidyl peptidase inhibitors
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
US20080234292A1 (en) * 2004-07-23 2008-09-25 Susan Marie Royalty Peptidase Inhibitors
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
EP3087975A1 (en) 2004-08-27 2016-11-02 Novartis Ag Treatment with vildagliptin
US7205323B2 (en) 2004-10-12 2007-04-17 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors pharmaceutical compositions containing them, and process for their preparation
US20070238728A1 (en) * 2004-10-12 2007-10-11 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them
US20070232608A1 (en) * 2004-10-12 2007-10-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them
US7524844B2 (en) 2004-10-12 2009-04-28 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
US7538128B2 (en) 2004-10-12 2009-05-26 Glenmark Pharmaceuticals S.A. Dipeptidyl peptidase IV inhibitors, process for their preparation and compositions containing them
US20060116393A1 (en) * 2004-11-30 2006-06-01 Markus Boehringer Substituted pyrido [2,1-a] isoquinoline derivatives
US20100222340A1 (en) * 2004-11-30 2010-09-02 Markus Boehringer SUBSTITUTED PYRIDO [1,2-a] ISOQUINOLINE DERIVATIVES
WO2006066770A1 (en) 2004-12-20 2006-06-29 F.Hoffmann-La Roche Ag Cycloalkylamine derivatives
WO2006066747A1 (en) * 2004-12-20 2006-06-29 F. Hoffmann-La Roche Ag 4-aminopiperidine derivatives
US7683079B2 (en) 2004-12-20 2010-03-23 Hoffmann-La Roche Inc. 4-aminopiperidine derivatives
US20100087485A1 (en) * 2004-12-20 2010-04-08 Markus Boehringer 4-aminopiperidine derivatives
US20060135512A1 (en) * 2004-12-20 2006-06-22 Markus Boehringer Aminocycloalkanes as DPP-IV inhibitors
JP2008524276A (en) * 2004-12-20 2008-07-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 4-aminopiperidine derivatives
US20060135561A1 (en) * 2004-12-20 2006-06-22 Markus Boehringer 4-Aminopiperidine derivatives
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
US20060135767A1 (en) * 2004-12-21 2006-06-22 Jun Feng Dipeptidyl peptidase inhibitors
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US8076330B2 (en) 2005-04-22 2011-12-13 Amgen Inc. Dipeptidyl peptidase-IV inhibitors
US20100009961A1 (en) * 2005-04-22 2010-01-14 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-iv inhibitors
US20060270701A1 (en) * 2005-04-22 2006-11-30 Alantos Pharmaceuticals, Inc. Dipeptidyl peptidase-IV inhibitors
US20110112051A1 (en) * 2005-04-22 2011-05-12 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl Peptidase-IV Inhibitors
US20060264433A1 (en) * 2005-05-23 2006-11-23 Backes Bradley J Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060276410A1 (en) * 2005-05-25 2006-12-07 Campbell David A Compounds and methods for selective inhibition of dipeptidyl peptidase-iv
US20070098781A1 (en) * 2005-08-11 2007-05-03 Loeffler Bernd M Modified release compositions for DPP-IV inhibitors
US20080300251A1 (en) * 2005-09-05 2008-12-04 Sattigeri Jitendra A Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors
US20070060530A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US20070060528A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
US20090275750A1 (en) * 2005-09-16 2009-11-05 Jun Feng Dipeptidyl peptidase inhibitors
US8222411B2 (en) 2005-09-16 2012-07-17 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070066635A1 (en) * 2005-09-16 2007-03-22 Mark Andres Polymorphs of benzoate salt of 2-[[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
US20070066636A1 (en) * 2005-09-16 2007-03-22 Chyall Leonard J Polymorphs of tartrate salt of 2-[2-(3-(r)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6h-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
US20090054314A1 (en) * 2005-10-07 2009-02-26 Antonio Cruz Combined use of DPP-IV inhibitors and gastrin compounds
US20070099913A1 (en) * 2005-10-31 2007-05-03 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US7488725B2 (en) * 2005-10-31 2009-02-10 Bristol-Myers Squibb Co. Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
US20100222393A1 (en) * 2005-12-30 2010-09-02 Naresh Kumar Muscarinic receptor antagonists
WO2007077508A2 (en) 2005-12-30 2007-07-12 Ranbaxy Laboratories Limited Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors
US20100292172A1 (en) * 2006-03-21 2010-11-18 Amylin Pharmaceuticals, Inc. Peptide-Peptidase Inhibitor Conjugates and Methods of Using Same
US8759295B2 (en) 2006-03-21 2014-06-24 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
US20100029941A1 (en) * 2006-03-28 2010-02-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
US7960384B2 (en) 2006-03-28 2011-06-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US20070244177A1 (en) * 2006-04-12 2007-10-18 Probiodrug Ag Enzyme inhibitors
US20100234397A1 (en) * 2006-04-12 2010-09-16 Probiodrug Ag Enzyme inhibitors
US7728146B2 (en) 2006-04-12 2010-06-01 Probiodrug Ag Enzyme inhibitors
EP2636680A2 (en) 2006-05-26 2013-09-11 Amylin Pharmaceuticals, LLC Composition and methods for treatment of congestive heart failure
US20080051383A1 (en) * 2006-07-06 2008-02-28 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US20080280931A1 (en) * 2006-11-29 2008-11-13 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20080227798A1 (en) * 2006-11-29 2008-09-18 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8084605B2 (en) 2006-11-29 2011-12-27 Kelly Ron C Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
US20080287476A1 (en) * 2007-03-13 2008-11-20 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
EP2865670A1 (en) 2007-04-18 2015-04-29 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
US20100291020A1 (en) * 2007-09-21 2010-11-18 Lupin Limited Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors
US8338450B2 (en) 2007-09-21 2012-12-25 Lupin Limited Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
US20100286365A1 (en) * 2007-09-27 2010-11-11 Amylin Pharmaceuticals, Inc. Peptide-peptidase-inhibitor conjugates and methods of making and using same
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
WO2010009243A1 (en) 2008-07-15 2010-01-21 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
US9061060B2 (en) 2008-07-15 2015-06-23 Theracos Inc. Deuterated benzylbenzene derivatives and methods of use
US20100063141A1 (en) * 2008-07-15 2010-03-11 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
US20100144140A1 (en) * 2008-12-10 2010-06-10 Novellus Systems, Inc. Methods for depositing tungsten films having low resistivity for gapfill applications
US8748457B2 (en) 2009-06-18 2014-06-10 Lupin Limited 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
WO2011029920A1 (en) 2009-09-11 2011-03-17 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
WO2011110613A1 (en) 2010-03-10 2011-09-15 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
WO2011153953A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9907848B2 (en) 2010-08-03 2018-03-06 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for treatment of metabolic disorders
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2014020462A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of vildagliptin intermediate
WO2014061031A1 (en) 2012-10-17 2014-04-24 Cadila Healthcare Limited 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders

Also Published As

Publication number Publication date Type
US6124305A (en) 2000-09-26 grant

Similar Documents

Publication Publication Date Title
US20030216450A1 (en) Inhibitors of dipeptidyl peptidase IV
US6245799B1 (en) [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
US5872138A (en) Thrombin inhibitors
US6268384B1 (en) Compounds possessing neuronal activity
US20050065196A1 (en) Azole compound and medicinal use thereof
US5612353A (en) Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US20040082497A1 (en) Inhibitors of dipeptidyl peptidase IV
US4954502A (en) 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US7217701B2 (en) Intracellular calcium concentration increase inhibitors
US20060223861A1 (en) Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
US20070197522A1 (en) Dpp-iv inhibitors
US6562828B1 (en) Amidine compounds
Tsou et al. A convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP
US7205409B2 (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US20040236102A1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US5475109A (en) Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
US20040254167A1 (en) Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US6653338B2 (en) FSH mimetics for the treatment of infertility
US20040106656A1 (en) Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2003072197A1 (en) Acc inhibitors
EP0507534A1 (en) Succinic acid compounds
WO2005116029A1 (en) Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US20050043292A1 (en) Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
US5883094A (en) Benzimidazolone derivatives with central dopaminergic activity
US5874428A (en) N-substituted aza-heterocyclic carboxylic acids and esters thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: NOVARTIS AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VILLHAUER, EDWIN BERNARD;REEL/FRAME:010345/0349

Effective date: 19991007

FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12